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ABSTRACT 
The nasal administration of drugs, particularly peptides, is very beneficial but 
like other mucosal routes, suffers from low bioavailability for the higher 
molecular weight compounds. The nasal bioavailability of peptides and proteins 
is influenced by the dosage form as well as the devices used for administration. 
In the present study an effort was made to investigate the effect of formulation 
and device variables on the intranasal delivery and absorption of salmon 
calcitonin (sCT). The formulations were designed as nasal sprays with viscosity 
of 1 and 76 cps using methylcellulose as a viscosity enhancing agent at 0 and 1 % 
w /w; tonicity of 100 mOsm, 300 mOsm and 600 mOsm using sodium chloride as 
a tonicit y adjusting agent; an acidic phospholipid, 
Dimyristoylphosphatidylglycerol (DMPG), as an absorption enhancer at 1 % 
w /wand chlorobutanol as the preservative. The formulations were investigated 
for viscosity by using a cone and plate viscometer and for droplet size 
distribution with a Malvern laser sizer. The selected formulations were delivered 
to the nasal cavity of healthy male New Zealand rabbits using a commercially 
available metered spray pump and a prototype device, nasal micron spray 
pump, to facilitate a uniform distribution of the spray in the nasal cavity. The 
components of the devices, mechanism of pump and actuator design were 
evaluated for dose accuracy as well as their ability to generate a uniform 
distribution of spray in the nasal cavity. A full factorial design with tonicity at 
three levels, viscosity at two levels and concentration of enhancer at two levels 
was used as the experimental design. Serum levels of sCT were determined using 
a double antibody radioimrnunoassay. The area under the curve (AUC) and 
bioavailability were determined using pharrnacokinetic software MKDATA. The 
pharmacodynamic effect of salmon calcitonin of lowering of calcium was 
measured, by complexation with arsenazo III, using a visible spectrophotometric 
technique at 650 nm. The data was analyzed using ANOVA and the comparisons 
among the treatments were performed using• Scheffe 's multiple comparison 
analysis and Fisher's least significance test. Deviation from isotonicity (300 
mOsm) enhanced the intranasal bioavailability of sCT by 4-5 fold while the 
addition of DMPG at a concentration of 1 % w /w doubled the bioavailability. 
Variation in the viscosity of formulations did not influence the bioavailability of 
salmon calcitonin. The data was interpreted using response surface methodology 
(RSM) with canonical analysis parameters demonstrating that optimum 
formulations could be designed. 
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PREFACE 
I elected to write this dissertation following the format of the manuscript plan 
described in section 11-3 of the graduate manual at the University of Rhode 
Island. This option was most appropriate to present my results in various 
sections. 
Section I consists of a general introduction of the topic and the objectives of my 
investigation. The three manuscripts, in Section II are the core of this study. 
Section III contains a set of appendices A to C giving experimental details and 
supporting data for the three manuscripts presented in Section II. 
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SECTION I 
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INTRODUCTION 
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Recent years have seen enormous advances in the field of protein and 
peptide engineering and a greater understanding of the way in which 
biological response modifiers function in the body. It is now possible through 
the use of recombinant DNA techniques, or by solid phase protein synthesis, 
to produce significant quantities of a wide variety of proteins and polypeptide 
hormones that are therapeutically active. The list of these response modifiers 
includes interferons, macrophage activation fa ctors, neuropeptides and 
proteins that may have potential in cardiovascular diseases, inflammation, 
' contraception etc Prospects of using some of these materials in medicine 
h ave reached the stage where products have either been approved by 
regulatory authorities or are the subject of applications as investigational 
drugs or as new ~herapeutic agents . In most cases these agents are 
administered by injection, however those agents which are indicated for 
chronic therapy need to be administered by appropriate delivery systems. 
Unfortunately the research technology for development of delivery systems 
for peptides and proteins has not kept pace with the rapid progress in 
biotechnology and consequently there are presently few systems that are 
entirely appropriate for the administration of macromolecules. Furthermore 
essential pharmacokinetic and correlative pharmacodynamic data is often 
missing, for example questions like where and how does the peptide 
function?, what dose is needed and how often should it be given?. 
Many of these obstacles are rela ted to the properties that set peptides and 
p roteins apart from the vast majority of drug substances in use today. These 
properties include molecular size, susceptibility to proteolytic breakdown, 
rapid plasma clearance, peculiar dose-response curves, immunogenicity, 
3 
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biocompatibility and the tendency of peptide or protein to undergo 
aggregation, adsorption and denaturation. Therefore existing drug delivery 
systems must be modified and novel ones must be developed to overcome 
these obstaclesl. 
Although the biotechnology industry has prompted a resurgence of interest 
in noninvasive delivery systems, there have been studies performed as early 
as 1922 investigating the efficacy of insulin by intranasal, oral, rectal and 
vaginal routes2 . This early work and that of others up to the 1960's met with 
little success. However these studies served to ill ustrate the major problems 
of noninvasive delivery which are low bioavailability, unreliable dosing, and 
acute local toxicity of formulations using permeation enhancers; these 
problems still remain the major challenges3-7. 
Some of the noninvasive routes investigated in the recent years are oral, 
ocular, buccal, pulmonary, transdermal, rectal, vaginal and nasal. For each 
route of delivery, there are two potential barriers to absorption, poor 
permeability and enzymatic barriers. The problems of poor permeability, high 
inter subject variability and acute toxicity associated with delivering protein 
and peptide drugs by noninvasive routes may be minimized by using 
enzymatic inhibitors and/ or novel absorption enhancers. The delivery by 
these routes may not be bioequivalent to invasive methods, however the 
convenience to patient will, in some cases, outweigh the demand for 
complete bioequivalence8 . 
The main emphasis is to rationally evaluate the problems for peptide and 
protein drug delivery systems and the options available for rational and 
4 
optimal drug delivery. 
Oral Delivery 
A wide variety of routes of administration and delivery systems exist, but by 
far the mos t popular approach is oral delivery where the drug is intended to 
be absorbed from the gastrointestinal tract (GIT). However the delivery of 
peptides and proteins v ia the GIT is difficult because of their inherent 
instability due to the presence of proteolytic enzymes and the poor 
permeability of the intestinal mucosa to high molecular weight polypeptides 
and proteins9. 
Although generally unsuccessful at present, the potential therapeutic and 
commercial benefits of successful oral delivery of peptides and proteins are 
sufficiently compelling to sustain research. The principal strategy has been the 
protection of a given peptide or protein from the proteolytic enzymes in the 
lumen of the gastrointestinal tract. Insulin was encapsulated with an 
impervious azopolymer film that remains intact in the GIT until it reaches 
the large intestine. Once in the colon, the azo bonds of the polymer are 
reduced by the indigenous microflora releasing the peptide. This strategy was 
used for vasopressin and insulin and biologically active amounts were 
absorbed into the blood stream of the rat. In spite of these encouraging results, 
the general utility of this approach in oral delivery is far from certain and 
requires additional information on the effects of both bacterial proteolytic 
enzymes on peptide stability and fecal matter on peptide absorption within 
the colonlO. 
The less than successful delivery of oral dosage forms for proteins and 
5 
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polypeptides has led to the investigation of alternative noninvasive routes 
such as transdermal or mucosal routes. Peptides and proteins when delivered 
via these alternative routes may be exposed to a smaller surface area, hence a 
smaller fraction of enzymes are present, as compared to the oral route. 
Peptides and proteins are subjected to less dilution via these routes since the 
resident fluid volume is less, thereby maximizing the concentration gradient 
for absorption . 
Transdermal Delivery 
The skin is composed of two major tissue layers . The outermost layer of the 
epidermis, the stratum corneum, is composed of thin flat, layered keratinized 
cells, 15 to 20 layers thick and is major barrier to skin permeation. The 
epidermis is much thinner than the dermis and is made up of stratified 
keratinized cells. The underlying layer, or dermis is extensively vascularized 
and contains a nerve network. While the stratum corneum lacks in enzymes, 
the next viable layers contain numerous enzymes that can degrade peptide 
and protein drugsll-12. 
The transdermal route has been successful in systemically delivering small 
drug molecules, such as scopolamine, nitroglycerine, clonidine, and estradiol. 
The delivery of peptide and protein has shown a greater resistance to 
absorption, primarily because of impermeability to the stratum corneum. At 
the present time it seems highly unlikely that the simple application of a 
peptide in a vehicle to the skin will produce suitable clinical effects13. The 
enhancement of peptide/protein skin permeation via electric current, 
iontophoresis, has shown some promise for the transdermal delivery of these 
6 
drugs. This mode of delivery may have the potential to deliver the drug in a 
pulsaltile manner, which is critical for the desired physiological response of 
some of the hormonal drugs14-15 . 
However the iontophoretic transport of gonadotrophin-releasing hormone 
(GnRH), produced erratic results16 . The LHRH analog, leuprolide, was 
explored for iontophoretic facilitated transport and there was no measurable 
flux at 0.SVl 7. Results obtained with the thyrotropin releasing hormone in 
nude mouse skin18 and insulin in albino rabbit skin19 indicated that 
iontophoresis offers benefits only w hen the integrity of the stratum corneum 
is compromised. In contrast, Siddiqui et al, reported iontophoretic facilitated 
transport of insulin across the skin of diabetic rats without first stripping the 
stratum corneum, although there were significant inter-animal variations in 
the extent of blood glucose lowering20. 
No explanation has been suggested for these discrepancies in the role of the 
stratum corneum in limiting transdermal insulin absorption during 
iontophoresis. These equivocal results, coupled with the uncertain long-term 
effects of applied current on the skin cast doubt on the viability of 
iontophoresis as a routine, noninvasive technique to improve transdermal 
peptide and protein delivery21 . 
Ocular Delivery 
The visible part of the eye consists of the iris and the sclera. The iris is covered 
by cornea and the sclera is covered by a conjunctiva! membrane. Absorption 
primarily occurs through the cornea or the conjunctiva! membrane. 
7 
( 
The systemic absorption of peptides and proteins may occur through contact 
with the conjunctiva and the nasal mucosa, the latter occuring as the result of 
drainage through the nasolacrimal duct . For optimal systemic delivery the 
absorption through the conjuctival and nasal mucosa must be maximized. 
The main difficulty in the delivery of drugs to the eye is the rapid removal of 
the substances by blinking and drainage through the lacrimal duct and the 
low permeability of the cornea22 . There is a significant level of 
aminopeptidases in the eye fluids and tissues which may degrade the 
peptides23. 
Several investigators have studied the delivery of peptides and proteins into 
the systemic circulation by the ocular route24-29 . It has been demonstrated 
that it is not possible to achieve therapeutic levels of insulin without the use 
of a permeation enhancer. The bioavailability of insulin was improved by 
coadministration of permeation enhancers such as polyoxyethylene-9-lauryl 
ether, sodium deoxychlolate, sodium glycocholate. Over 80% of the insulin 
reaching the systemic circulation was found to be absorbed through the nasal 
mucosa and the absorption pattern followed that reported for nasal delivery 
quite closely30. The coadministration of permeation enhancers offers 
promising results but their long term effects on the ocular physiology and 
histology need further characterization. 
Pulmonary Delivery 
Pulmonary delivery systems have also been considered as a method of 
improving the bioavailability of peptide and proteins because of certain 
8 
advantageous features offered by the lung. The walls of the alveoli in the 
deep lung are extremely thin (0.1 to 1 µm) as compared to the capillary walls 
(7 µm) or red blood cells (8 µm) . They are an order of magnitude thinner than 
typical mucosa! or epithelial membranes, which are several milllimeters 
thick . In ad dition the surface area of the lung is extremely large, 
approximately 75 m2 for a 70 kg male. Furthermore one puff of an aerosol 
administered correctly can cover this surface area within seconds31. 
However the lungs are rich in enzymes . Virtually all known peptide 
hydrolases (exopeptidases and proteinases) are present in the lung tissue. 
Several membrane-bound peptidases exist on pulmonary vascular surfaces 
and a wide varie ty of proteinases are present in other lung cells. Several 
peptidases are distributed throughout the lung and they may be impossible to 
saturate and can cause rapid degradation of peptides32. 
The particle size distribution of aerosolized drug is very critical to the 
bioavailability of the aerosol formulations . The particle size often defined as 
mass median aerodynamic diameter (MMAD), must be approximately 5 µm 
or less in order for drug particles to reach lung. A major concern with aerosol 
formulations is the denaturation of peptides and proteins during shaking and 
aerosolization, the dispersibility, the particle size as well as the more common 
concerns of chemical stability, safety and efficacy. A typical distribution of dose 
delivered from a metered dose inhaler indicated that only 4.7% of the 
delivered dose actually r aches the peripheral lung and 6.3°/.1 reaches the 
central lung33. 
The absorption of the fraction of the drug that is able to reach the lung 
9 
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depends upon factors singular to respiratory system, such as tidal volume, 
respiratory rate, respiratory pause, respiratory distress syndrome, lung 
volume, emboli, total lung burden, solubilization in alveolar macrophages, 
recirculation, pancreatitis, exercise, interstitial lwi.g diseases etc34 . Thus a lot 
of variables besides the formulation variables have to be taken into account 
for optimal delivery by pulmonary route. 
Buccal Delivery 
The buccal membrane is similar to the skin in that it is a stratified squamous 
epithelium, with cellular extrusion products filling the intercellular spaces. 
The buccal enzymatic barrier is greater than other routes and enzyme activity 
has been reported to be greater than at the vaginal or nasal mucosa. 
However, the buccal route offers convenience and is generally more 
acceptable to the patient than other routes. This route of delivery offers a 
much larger and easily accessible area for placement of delivery systems such 
as adhesive tablets, but there may be a risk of drug degradation by accidental 
swallowing or by the salivary wash-out of the tablet. Therefore the preferred 
dosage form for buccal delivery is bioadhesive patches. The formulation 
aspects of bioadhesive patches include variables such as the type of polymers 
used, the viscosity grade of the polymers, and the amount of polymer per 
patch which can further aid in optimizing the formulation35 . 
Permeability offered by buccal route is often poor as compared to other 
mucosal routes. Investigation of the buccal delivery of protirelin indicated 
the buccal dose required to achieve an equivalent pharmacodynarnic response 
10 
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was about 200 times higher than that for iv injection of the peptide. Thus 
bioadhesive patches alone may not improve bioavailability sufficiently to 
reach therapeutic levels and may require the coadministration of permeation 
enhancers36. 
Rectal Delivery 
The human rectum offers a surface area of 200 to 400 cm2. It is abundant in 
blood, lymphatic vessels, and microflora and has a fairly constant 
environment with respect to temperature, pH, and viscosity of rectal fluid37. 
The enzymatic degradation of model enkephalin peptides has been shown to 
be greatest in rectum and an absorption enhancer is required to achieve 
therapeutic levels . 
The dosage forms for rectal delivery of peptides and proteins are usually more 
conventional such as solutions, gels, and suppositories. Of these, gels are the 
most efficient because they offer a proper balance between retention at the site 
of administration and the rate of peptide release38. It was demonstrated that 
the rectal bioavailability of [Asul, 7]-eel calcitonin in the rat was best from a 
0.1 % polyacrylic acid gel when compared with other dosage forms such as 
saline, a triglyceride fatty acid mixture base, and a polyethylene glycol 1000 
base. Following administration, solutions tend to spread away from the 
rectum into the ascending colon and from there into portal rather than 
general circulation39 thereby resulting in reduced peptide and protein 
bioavailability. Recently, more sophisticated systems such as the osmotic 
pumps and hydrogel cylinders have been investigated as rate-controlled rectal 
11 
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drug delivery systems, and while the results have been positive, these dosage 
forms have not yet been tested with peptide and proteins40-41. 
There does not seem to be significant absorption via rectal route without the 
use of a permeation enhancer as demonstrated by the delivery of des-
glycinamide arginine-vasopressin which when enhanced with STDHF 
reached an optimum concentration of 4'Y.,42. 
How ever the lack of acceptability of this route by many patients and the 
interruption of delivery by defecation makes this route less desirable than 
other routes43 . 
Nasal Delivery 
The epithelial cells of the nasal mucosa are covered with numerous 
microvilli and increase the surface available for drug absorption. The nasal 
cavity offers a high surface area of approximately 150 cm2 for absorption. 
Furthermore the subepithelial layer is highly vascularized with large and 
fenestrated capillaries specially designed for the rapid passage of fluid through 
the vascular wall. The venous blood draining from the nose passes directly 
into the systemic circulation and is well suited for the absorption of drugs that 
are extensively metabolized44. 
Nasal administra tion of nonpeptide drugs or peptides of ten residues or less 
has been very successful. Some examples are oxytocin, vasopressin and its 
analog desmopressin acetate (DDA VP); and luteinizing hormone-releasing 
hormone (LHRH) and its superanalogs buserelin, leuprolide, and nafarelin. 
12 
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However when the number of amino acids is increased to 20 or greater, as in 
insulin, glucagon or growth hormone releasing hormone, low bioavailability 
results except when delivered with an enhancer45-46. 
The nasal bioavailability of peptides and proteins is influenced by the dosage 
form as well as the technique of administration. The most popular dosage 
form has been the aqueous solution, although gels, powders and 
microspheres have been investigated. 
The nasal administration of drugs, particularly peptides, is very advantageous 
but like other routes suffers from low bioavailability. To achieve 
reproducibility with dosing and provide acceptable economy in the treatment, 
a bioavailability of 1-2'X, for an expensive recombinant peptide must be 
improved. It is necessary to optimize both the techniques of administration 
and the nasal formulations to provide a sufficient level of drug absorption. 
The optimal nasal absorption delivery system should be well tolerated, 
inexpensive, should have low toxicity and reasonable bioavailability. Starch 
microspheres, water insoluble and swellable powders and phospholipids are 
novel absorption systems which have promising properties but need further 
characterization47. 
There are a number of noninvasive routes available for the delivery of 
polypeptides and proteins but all suffer from the obvious disadvantage of 
proteolytic activity and poor permeability to higher molecular weight 
molecules. However, with the administration of either enzymes inhibitors or 
protective polymers, or perhaps permeation enhancers, bioavailability can be 
13 
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substantially improved. Even though bioavailability by these routes may still 
be fairly low, the advantages of noninvasive therapy certainly outweigh the 
disadvantages . 
A comparison of different routes for the delivery of protirelin via nasal, 
buccal, peroral and iv demonstrated that nasal administration was 10-times 
more efficient than the buccal route. Based on the pharmacodynamic effects 
observed, the nasal dose had to be five times higher than iv dose, whereas the 
buccal dose had to be forty times the nasal dose48 . 
Of all the alternative routes, the nasal route has received the most attention 
to date . Nasal delivery has the potential of being an extremely effective route 
for systemic administration of peptides and proteins . The selection of proper 
formulation parameters such as the pH of the vehicle, buffer species and 
concentration, ionic strength, viscosity, charge, osmolarity, type and 
concentration of preservatives as well as delivery with an appropriate device 
such as nasal spray pump, compressed air nebulizer, instillation catheter and 
dry powder insufflator could further influence and optimize the absorption of 
peptide and proteins. 
14 
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The objectives of the present research were: 
1. To identify the formulation and device variables that are critical in 
enhancing the low intranasal absorption of the polypeptide, salmon 
calcitonin. 
2. To systematically characterize the effect of formulation and device 
variables on the droplet size distribution and dynamics of spray 
profile. 
3 To study the primary and interactive effects of varying levels of 
viscosity and tonicity on the nasal absorption of salmon calcitonin. 
4. To study the effect of the novel absorption enhancer, 
Dimyristoylphosphatidylglycerol (DMPG) on the absorption of salmon 
ca lei tonin. 
5. To characterize the optimal calcium lowering response of salmon 
calcitonin as a function of salt concentration, viscosity and concentration 
of absorption enhancer, dimyristoylphosphatidylglycerol. 
6. To demonstrate the use of response surface methodology (RSM) as an 
aid in determining optimal formulations . 
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MANUSCRIPT I 
EVALUATION OF FORMULATION AND DELIVERY DEVICE 
VARIABLES ON NASAL SPRAY CHARACTERISTICS 
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ABSTRACT 
The aim of this study was to evaluate the effect of formulation variables; 
viscosity, tonicity, concentration of absorption enhancer and nasal delivery 
devices; mechanical metered nasal spray pumps,. pump components and a 
prototype device, the nasal micron spray pump on the spray characteristics 
and dose administration of a model nasal product. Formulations were 
prepared within specified ranges of viscosity (1 to 380 cps), tonicity (100, 300 
and 600 mOsms) and absorption enhancer (0 and 0.5% w /w). Viscosity was 
determined using a Brookfield cone and plate viscometer. The spray 
characteristics of the formulations were analyzed with a Malvern laser sizer 
and evaluated by characterizing the size distribution of the sprayed droplets 
using MSO and M90 parameters . For the metered nasal spray pumps, results 
indicated that among the formulation variables, increasing viscosity or 
addition of an absorption enhancer increased droplet size and produced a 
deviation from a Gaussian size distribution of the sprayed droplets. It was not 
possible to spray any solution greater than 2.12 cps and maintain .a Gaussian 
spray distribution with a metered nasal spray pump. Tonicity did not 
demonstrate any significant effect on the droplet size distribution. Changes in 
pump based on two different mechanisms of spray delivery or actuator 
assembly design based on the orifice diameter or spray angle of spray insert 
did not produce any significant differences in spray characteristics. However 
with the use of a prototype device, the nasal micron spray pump, it was 
possible to spray solutions up to a viscosity of 76 cps as a fine spray. 
Key words: Spray characteristics, Malvern laser sizer, Metered nasal spray 
pump, Formulation variables, Device variables, Nasal micron spray pump 
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INTRODUCTION 
>( 
)( {§.everal types of delivery devices such as nasal pump sprayers, compressed air 
nebulizers, instillation catheters and dry powder insufflators are used to 
adminis ter drugs to the nose. There are mechanistic variations in these 
devices that produce d ifferences in the delivery of a drug in terms of volume 
and reproducibil it~ he instillation catheter has high accuracy but only a 
small volume, less than 50 µ l, therefore limited doses can be delivered. An 
aerosol spray can deliver higher volumes, up to 140 µl bu t the amount of 
active ingredients delivered is limited by drug solub ility and viscosity. Dry 
pow ders offer the option of delivering the highest mass of active ingredients 
because they may not formulated to contain a carrier vehicle. Thus 100% of 
mass delivered can be active ingredient. Reproducibility is also an important 
factor . Administration by instillation catheter and compressed air nebulizer 
have been shown to provide good reproducibility with respect to the amount 
of material delivered. On the other hand administration by a nasal spray 
pump or dry powder insufflator have been found to be considerably more 
variable particularly with respect to amount of material deposited in the 
nosel . 
~ [These devices influence the mode in which the drug is administered, ie., 
whether the drug is delivered as drops, aerosol or spray. The mode of drug 
administration can affect drug distribution in the nasal cavity, which in turn 
influences bioavailabili ty of a drug. It has been demonstrated that significant 
differences in drug distribution were observed when drug was administered 
by catheter, mechanical metered nasal spray pump and metered dose 
27 
pressurized aerosol. The results indicated that the metered nasal spray pump 
gave a constant dose and a very good nasal mucosa! distribution2, 3. J » 
,..-
. Delivery devices as well as the density, shape, hygroscopicity of the particles 
\... 
and the particle size distribution affect the deposition site within the nasal 
cavity. The deposition site in turn influences the extent and rate of absorption 
which in turn is dependent on ciliary movement and/or diffusion in the 
mucous layer and su sequently the biological response in experimental 
'I 
animals and human~§. uniform distribution of particles throughout the 
nasal cavity may be achieved by delivering the particles from a nasal spray 
using a pressurized propellant. A metered dose delivery system developed for 
the nasal delivery of drugs could provide a consistent dose delivery and spray 
pattern which affects the deposition of droplets in the nasal cavity. Metered 
nasal spray devices have shown the ability to deposit well controlled doses in 
the nasal cavity which remain there for sufficient period to provide complete 
absorption4.J ¥ 
#' ~xperimental work has demonstrated that the relative bioa~.~_ilability and 
biologi5al response can be improved by adminstration of a drug via nasal 
spray pumps rather than by nasal drops. Nose drops disperse the dose 
throughout the length of the nasal cavity, from atrium to the nasopharynx. 
The nasal spray deposits droplets anteriorly in the nasal cavity with little or 
no dose reaching the turbinates. The drug deposited anteriorly in the nasal 
cavity remained in the nose longer while drops are cleared more rapidly than 
the dose administered as a sprays, 6. J .$ 
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;t- 01 addition to the proper choice of nasal device, it is imperative that studies 
be performed to select the variables such as concentration and volume of the 
dose to be sprayed for optimum intranasal delivery. Nasal bioavailability has 
been found to be a function of the volume and concentration of the nasal 
spray. It has been demonstrated that a formulation administered by two 50 µl 
sprays gave a biological response superior to that of same drug administered 
by one 100 µl dose7 . Thus both administration devic~ and formulation 
desi n can affect drug distribution, deposition and the clearance process from 
the nasal cavity, leading to modifications in th biopharmaceutical aspects 
and bioavailability of the drug administered ] 1' 
Despite the fact that nasal delivery devices have been available for over a 
decade there is still very little fundamental information as to how variations 
in the design of a nasal pump assembly can interact with the formulation 
variables and affect the dynamics of spray plume, droplet size, spray 
deposition and distribution in the nasal cavity. This information along with 
an understanding of nasal formulation parameters could aid in optimized 
products designed to enhance bioavailability. This paper documents the nasal 
devices and their interaction with the formulation variables. 
In this study two types of nasal spray devices; a metered nasal spray pump and 
its mechanical components i.e., mechanism of pump, design of actuator and a 
prototype device, the nasal micron spray pump were studied. 
The metered nasal spray pump is a d rug delivery device that administers a 
predetermined volume of formulation into the nasal cavity. It has been 
successfully utilized commercially in the administration of several locally 
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acting drugs, such as corticosteroids (Extracort, Syntaris ), beclornethasone 
dipropionate (Aldecin, Beconase, Becotide, Vancenase), flunisolide 
(Nasalide), trarnazoline (Tobispray), and nasal decongestants (Rhinospray, 
Otrivin, Afrin, Nostril, Nostrilla , Dris tan); and is also used for the systemic 
delivery of calcitonin (Calcitonina, Calsynar), nafarelin acetate (Synarel), 
crornolyn acetate (Nasalcrorn), insulin, desmopressin acetate, nitroglycerin. 
A typical nasal spray pump is composed of 10-13 spray components, to include 
metering chamber (5-7), actuator (2-3) and closure (2) components. 
The metered nasal spray pump is available as (i) a ball and spring pump or (ii) 
a dual spring compression pump. As the names suggest, these pumps use two 
different mechanisms to aspirate the liquid from container and to release the 
spray. The ball and spring pump is composed of a cylinder, shut off valve 
(ball), spring, piston, stern, and a device for connection to the actuator. The 
dual spring compression or precornpression pump is composed of piston, 
diptube and twin springs; these twin springs help to aspirate the liquid from 
container and also act as a shut off valve. 
The actuator in a mechanical nasal spray pump aids in expelling the liquid 
mass aspirated by the pump assembly or metering chamber. Actuators are 
available as a one or two piece assembly and house a spray insert with a 
specified diameter to expel the liquid as spray. When a pump is actuated, a 
dose volume aliquot is released from the metering chamber and travels as a 
liquid mass until it encounters the restriction of the orifice of the spray insert. 
This restriction may have a series of spiral baffles, which begin the liquid 
breakup and impart a spinning motion to the liquid resulting in the spray 
mist. The spray pattern is determined by the number of spiral baffles and is 
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used to produce a wide (50-700) or narrow (20-40°) spray cone. Droplet size is 
dependent upon force of the liquid mass striking the orifice, plus the design 
of the baffles, the diameter of the opening as well as the characteristics of the 
liquid itself. 
It has been previously demonstrated that the addition of a viscosity 
enhancing agent increases contact time in the nose by reducing the rate of 
mucociliary clearance of the dosage form and may help to enhance the 
activ ity by increasing the "window" of absorption for the administered drug. 
Viscosity also seems to change the pattern of deposition and clearances. 
However previous studies have investigated viscosity in the range of 1-3.5 
cps, which can be considered as low viscosity solutions. The nasal micron 
spray pump (NMSP), a prototype device originally developed for 
administration of pulmonary inhalation solutions (figure 1) was used in this 
study to investigate the feasibility of using the device to deliver solutions of 
higher viscosity to the nose. The NMSP is a hand actuated propellent free 
spray device that is capable of producing a fine spray. The physical and 
technical requirements have been achieved by using an air blast nozzle 
(figure 2). The air blast nozzle is the heart of this spray device and its 
geometry is mainly responsible for the ability to generate small droplets 
especially for viscous solutions. The nozzle consists of a mixing chamber 
whose volume is partly filled by a polyurethane sponge with open pores. The 
NMSP also consists of two pumps, a liquid metering pump and an air pump. 
When the device is actuated by turning the top part in a rotational motion, a 
liquid volume is metered into the mixing chamber simultaneously. The 
device is now primed. By pressing the actuation button the air valve opens 
and air starts to flow through the nozzle and is compressed. This compressed 
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air expands through the nozzle system with increasing velocity. The solution 
is now accelerated by the expanding ambient air leaving the nozzle and the 
kinetic energy of the air stream pushes and shears the liquid which was 
previously dispersed in the sponge and thus disintegrates the liquid into 
small droplets9 
The geometry of air blast nozzle of the NMSP provides a huge improvement 
as compared to the metered nasal spray pump which uses a mechanical 
actuator to spray the liquid mass. The use of this new device for nasal 
delivery could be in aluable for administering the drugs in high viscosity 
solutions because it is able to generate a fine mist of spray for distribution into 
the nasal cavity9. 
Nasal devices are capable of generating different spray profiles because of the 
different types of components which makeup the functional unit. The 
literature shows no investigation of the influence of nasal administration 
device variables on spray characteristics. Likewise the spray characteristics 
may also be affected by the formulation variables. 
Since it is strongly postulated that the functional components of a nasal 
pump assembly can interact with the formulation variables and affect the 
dynamics of spray profile, spray deposition and distribution in the nasal 
cavity; it was decided to evaluate the influence of the formulation variables: 
viscosity, tonicity, concentration of absorption enhancer with the nasal 
administration device variables : mechanism of pump (ball and spring versus 
dual spring compression pump), design of actuator (orifice diameter of spray 
insert, spray angle), on the spray characteristics and droplet size distribution. 
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EXPERIMENTAL 
Materials 
Methylcellulose, Methocel A15C Premium (Dow Chemical Co., Midland, MI) 
w as used as a viscosity enhancing agent in the concentration of 0.25%-2% 
w /w. Sodium Chloride (Fisher Scientific, Fairlawn, NJ) was used to adjust 
tonicity . Dimyristoylphosphatidylglycerol (Avanti Polar Lipids, Alabaster, AL) 
was used in the concentration of 0.5% as absorption enhancer. Chlorbutanol 
0.5% w /w (Sigma Chemical Co., St. Louis, MO) was used as a preservative. 
Methodology 
Selection of formulation variables 
Viscosity 
Methylcellulose (Methocel), a natural carbohydrate that contains a repeating 
structure of anhydroglucose units was chosen as a viscosity enhancing agent. 
It is odorless and colorless. The premium grade was chosen as it is a GRAS 
substance and approved by FDA. Formulations containing methylcellulose 
were prepared in concentrations ranging from 0.25% to 2%. 
Tonicity 
Tonicity was investigated at three levels using sodium chloride as a tonicity 
adjusting agent. Formulations were prepared at 600 mOsms (hypertonic), 300 
mOsm (isotonic) and 100 mOsms (hypotonic). 
Absorption Enhancer 
Dimyristoylphosphatidylglycerol, an acidic phospholipid, a novel permeation 
enhancer was used at a concentration of 0.5% w /w. 
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Preservative 
Chlorbutanol, a lipophilic preservative, 0.5% w /w was used as a preservative. 
Preparation of Formulations 
The formulations were prepared with a concentration of methylcellulose 
ranging from 0.25% to 2% in a sodium acetate-acetic acid buffer at pH 4. 
Methylcellulose was dispered in hot water (90-95° C) and stirred until all the 
particles were hydrated. Cold water was added slowly to the above mixture, 
the mixture was kept in an ice bath. The above dispersion was agitated for 3-4 
hrs, the specified quantity of sodium chloride was added depending upon the 
osmolarity required for the formulation and then stored in a refrigerator 
overnight. The dispersion was brought to the pH 4 with buffer after bringing 
it to the room temperature. All the formulations were filled into 4 ml clear, 
round, Type I glass serum vials equipped with metered pumps. 
Determination of Viscosity 
The viscosity of all the formulations was determined using a Brookfield cone-
plate viscometer, Model DV II. This cone-plate viscometer is equipped with a 
detachable "cone" and can be used with cones ranging from 0.8 to 30 radians. 
Cone, CP 52D, diameter of 2.4 ems and a cone of 3° was selected to carry out 
the viscosity determinations at 25°C. The viscometer was calibrated using 
standards ranging from 1 to 500 cps. Viscosity was determined at rotational 
speeds ranging from 0.5 to 100 rpm. Shear torque readings were recorded at 
each rotational speed. 
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Selection of delivery systems for intranasal drug administration 
There has not been any investigation of the interaction of the components of 
a spray pump and the formulation variables on the spray profile and droplet 
size distribution. The evaluation of the metered nasal spray pumps was 
performed using the different available components of (i) pump mechanism 
ie., ball and spring (Pfeiffer); dual spring compression (Valois) (ii) orifice 
diameter of the actuator ie ., 0.1 mm, 0.3 mm and 0.7 mm and (iii) angle of 
spray of the actuator ie., 200, 350, 60o. 
Dose reproducibity studies 
After priming of the pumps the weight loss per spray actuation was recorded 
for 10 consecutive strokes and arithmetic mean and standard deviation were 
calculated. Since these devices would later be used to administer the drug in 
bioavailability studies and since the dose was to be administerd within a 
interval of 60 minutes to the experimental animals, the dose accuracy was 
measured after 1 hr to determine if a second priming stroke was required 
before the second dose was administered. The procedure was also repeated, 
after 24 hrs. 
Screening of Nasal Devices 
An initial qualitative screening was performed with formulations ranging in 
viscosity (1 cps to 380 cps), tonicity (100, 300 and 600 mOsm) and concentration 
of the absorption enhancer (0 and 0.5% w / w) in combination with the 
various nasal device components such as the type of pump and actuator 
design etc. The initial evaluation of the spray profile was obtained by spraying 
against a background of black and white. The spray pattern was categorized as 
a fine spray, stream or stream with drops . Only the nasal spray devices 
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producing a fine spray were later used to d etermine the droplet size 
distribution using a Malvern laser sizer. 
D etermination of Droplet size using the Malvern laser sizer 
-- --- ----- - ... _ ... . -
The samples were analyzed using a Malvern laser particle sizer (Malvern 
t>iqll;aP ft. 3ooo c.ompuJe1... 
Instruments, Inc., Southborough, MA)., equipped with a t.600c analy:~ing w•tH, 
0-V'ld Dl61TAL. ~X6V CoIO..- N\Oni+D.- . ~~two.re,: mo.tver'l rrtas~i i..ez. 
NEC Powan:uate SX /1 6i computer._versi Q.. Ga-t acE[tti'St-ion-soft-wcrr , a ~tuXJ..re., 
spray synchronizer (PS51), and infrared trigger sensor (PS57), NEC Multisync 
2A monitor, and an Okidata Microline 320 dot m atrix printer. An adjustable 
m etal support bracket, to hold samples, was machined by Trans American 
Tool Co., Inc., Spring City, PA. The Malvern 2600c analyzing unit was 
equipped with a 300 mm range lens and configured as shown in figure 3. 
After performing a background measurement the sample bottle was 
positioned in the support at a distance of 10 cm from the actuator to the tip to 
the laser beam. The centerline of the bottle was 17 cm from the range lens. A 
"measure sample" command was executed from the key board prior to the 
actuation of the sample. Samples were actuated four times for each analysis. 
The analysis was performed in triplicate. The computer system was 
configured so that a total of 1000 sweeps (measurements) were executed 
during each analysis . The computer sweeps the detector at a rate of 
approximately 125 sweeps per second thereby giving the analyst sufficient 
time (about eight seconds) to perform four actuations per sample analysis of 
each sample. 
Statistical Analysis 
In order to determine the influence of the experimental variables on the 
spray characteristics, the measured droplet size distributions were subjected to 
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ANOVA. A completely randomized design was used. The analysis was 
performed using Statistical Analysis Software (SAS) and subjected to an F Test 
and hypothesis testing at 0.01 and 0.05 significance level. According to the 
hypothesis testing it was assumed that there was no difference among the 
droplet size measured and in cases where Fo was greater than F at 0.01 level 
and 0.05 levels, the hypothesis testing was rejected. Scheffe's 
multicomparison tes t were performed to further indicate significant 
differences among groups. 
RES UL TS AND DISCUSSION 
Viscosity studies 
The viscosity of the formulations varying in methylcellulose concentration 
was determined using a Brookfield cone and plate viscometer. The flow 
behavior was determined from a plot of shear rate versus shear stress(figure 
4). Methylcellulose exhibited a non-Newtonian flow behavior. There was a 
nonlinear relationship between the shear rate and shear stress for the 
methylcellulose indicating a deviation from the Newtonian behavior. Thus 
the viscosity was determined at a fixed rotational speed of 50 rpm. The 
viscosity at 50 rpm was found to be 1 cps for formulations without 
methylcellulose. The viscosity was calculated to be 2.12 cps, 11.35 cps, 76 and 
380 cps for formulations containing 0.25% w/w, 0.5% w/w, 1% w/w and 2% 
w /w of methylcellulose. 
Qualitative screening of formulations 
All prepared formulations were qualitatively screened. When the nasal 
devices with various actuator designs were tested ie., the metered spray pump 
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FIGURE 4 NON-NEWTONIAN FLOW EXHIBITED BY METHYLCELLULOSE 
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using either a ball and spring mechanism or a dual spring compression 
pump; the actuator designs with orifice diameters of spray insert of 0.1 mm, 
0.3 mm and 0.7 mm and spray angle, 200, 350 and 600 ; all the test 
combinations generated a fine spray when the buffer solution with a viscosity 
of lcps or a 0.25% w /w methylcellulose formulation with a viscosity of 2.12 
cps was sprayed. All the formul ations arying in tonicity, 300 mOsm, 600 
mOsm and 100 mOsm or concentration of absorption enhancer, 0% w /w and 
0.5% w /w produced a fine sp ray. However when formulations with 0.5% 
w / w methocel with a viscosity of 11.35 cps were tested with the various pump 
and actuator designs; all the test combinations generated a mixture of spray 
with drops. 
Formulations, with a viscosity greater than 11.35 cps were investigated using 
the (NMSP). It was determined that the NMSP was able to deliver all 
formulations up to viscosity of 76 cps generated by the 1 % w I w 
methylcellulose as a fine spray. However the viscosity generated by 2% w /w 
methylcelluilose (380 cps) and was released from the NMSP as a gel. 
Dose accuracy studies 
A total of 5-6 actuations were required to prime the metered nasal spray 
pump and ten actuations were required to prime the NMSP. This was 
determined b y m easuring the w eight loss per spray actuation for a 
formulation possessing a mean weight of SO mg fo r metered nasal spray 
pump and of 35 mg for the NMSP. The standard deviation was found to be 
±2% from the mean weight of the metered nasal spray pump and ±6% from 
the mean weight of the NMSP immediately after priming the pump. 
However, while the deviation for the metered nasal spray pump was found 
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FIGURE 5 DOSE REPRODUCIBILITY STUDIES OF NASAL DEVICES 
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to be ±2% from the mean weight; the NMSP showed a slight loss of primed 
value that increased the standard deviation to ±14% from the mean weight 
after 24 hrs (figure 5). 
Droplet size analysis 
Metered nasal spray pump 
When using a Malvern laser sizer to measure the droplet produced by spray 
pump, the M5o and M9o seemed to best characterize the size distribution. The 
parameter M5o represents average droplet size of 50% of the sprayed droplets 
and M9o represents an average size of 90°/t, of the sprayed droplet. The M5o for 
buffer formulations with a viscosity of 1 cps was 45.23±1.11 µm, and M9o was 
68.41±7.94 µm . The M 50 for 0.25% methylcellulose formulation with an 
increased viscosity of 2.12 cps was 56.97±3.45 µm and 130.22±13.59 µm for the 
M90 range. When increasing the methylcellulose to a 0.5% the viscosity was 
11.35 cps and the M 50 increased to 105.86±7.77 µm and the M 90 was 
305.04±18.54 µm . 
The influence of the formulation variable, viscosity, on the spray profile and 
droplet size analysis (figure 6), demonstrated that the average droplet size 
increased with higher concentrations of methylcellulose. However with this 
increase in viscosity the profile of droplet size deviated from a Gaussian 
distribution. An ANOVA of these formulations varying in viscosity indicated 
a significant difference at the M so and at the M 90. Scheffe 's multiple 
comparison test and Fisher's Least Significance test indicated that the droplet 
size distribution obtained from 1 cps and 2.12 cps was significantly different 
from the distribution produced by solutions with a viscosity of 11.35 cps. The 
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FIGURE 6 THE INFLUENCE OF VISCOSITY ON THE DROPLET SIZE DISTRIBUTION 
USING METERED NASAL SPRAY PUMP 
VISCOSITY 
1 _{c_Qs) 2.12 (cps) 11.35 (cps) 
N = 12 
AVERAGE 
S.DEV 
M50 
45.23 
1 . 11 
1 (cps) 
,_.., II 
II I• 
htllch .. w ·-·· 
ID 
l 
M90 M50 M90 M50 M90 
68.41 56.97 130.22 105.9 305 
·7.94 3.45 13.593 7 . 77 18.54 
2.12 (cps) 11.35 (cps) 
11 1 · r 11 
II 1• 
htllcl• tlw I"" ). 
10 
l 
I 
II IM 
fvhch .... 1 ..... 1 
ID 
l 
( average at the M9o level tends to produce a large standard deviation than that 
seen for the Mso. 
Isotonic formulations with a osmolarity of 300 mOsm generated a M so of 
45.23±1.15 µm, and M9o was 68.4±7.94 µm . Hypotonic formulations with a 
osmolarity of 100 mOsm generated a Mso of 45.07±0.34 µm and M9o was 76.32 
±2.49 µm . Hypertonic formulations with a osmolarity of 600 mOsm generated 
a Mso of 47.4±2.25 µm, and M9o was 130.37±2.25 µm. Thus the formulations 
varying in tonicity (figure 7) did not show any significant difference at Mso 
but did show a significant difference at M 90. Scheff e's multiple comparison 
test indicated that the droplet size distribution at M 90 obtained from the 
hypertonic formulation was significantly different from the isotonic and 
hypotonic formulations. The exact reason for this difference is not known. 
The addition of the absorption enhancer, Dimyristoylphosphatidylglycerol 
(DMPG) to the formulation also showed an increase in the Mso and M9o 
(figure 8). The Mso for formulations without DMPG was 45.23±1.11 µm, and 
M9o was 66.79±6.87 µm. However the addition of 0.5% DMPG provided a Mso 
of 71.16±3.18 µm, and a M9o of 133.07±0.79 µm. This increase may be due to 
the fact that the phospholipid forms a dispersion as compared to the solution 
seen for the previous formulations. Formulations varying in the 
concentration of absorption enhancer indicated a significant difference at Mso 
and at M90 as shown by the Scheffe's multiple comparison test at p<0.01. 
Among the device variables, the droplet size distribution and spray profiles 
for the two different designs of the nasal spray pump are shown in figure 9. 
The Mso for buffer formulations sprayed with a ball and spring pump was 
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FIGURE 7 THE INFLUENCE OF TONI CITY ON THE DROPLET SIZE DISTRIBUTION 
USING METERED NASAL SPRAY PUMP 
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FIGURE 8 THE INFLUENCE OF CONCENTRATION OF ABSORPTION ENHANCER ON 
THE DROPLET SIZE DISTRIBUTION USING METERED NASAL SPRAY PUMP 
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FIGURE 9 THE INFLUENCE OF MECHANISM OF PUMP ON THE DROPLET SIZE 
DISTRIBUTION FOR METERED NASAL SPRAY PUMP 
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44.37±0.459 µm, and the M 90 was 76.64±1.01 µm. The M so for buffer 
formulations sprayed using a dual spring compression pump was 47.42±2.24 
µm, and the Mgo was 106.54±35.22 µm. The influence of the orifice diameter 
of the spray insert is shown in figure 10. The M so for buffer formulations 
sprayed using an actuator with 0.1 mm spray insert was 45.23±1.15 µm and the 
Mgo was 68.41±7.94 µrn . The M5o for buffer formulations sprayed using a 
spray insert with a diameter of 0.3 mm was 45.64±0.34 µm, and the M9o was 
77.45±2.81 µm. The M5o for buffer formulations sprayed with a spray insert 
with a diameter of 0.7 mm was 47.40±2.25 µm and the M9o was 123.6±24.86 
µm . Similarly the effect of spray angle is shown in figure 11. The Mso for 
buffer formulations sprayed from an orifice with a spray angle of 20° was 
45.28±1.05 µm and the Mgo was 67.51±7.94 µm. Using spray angle of 35° the 
M5o for buffer formulations sprayed was 45.07±0.34µm, and the M9o was 
76.56±2.4 µm. The Mso for buffer formulations sprayed with a spray angle of 
600 was 47.57±3.4 µrn, and the M9o was 124.93±40.34 µm. Statistical analysis of 
the results indicated that there was not any significant difference at 0.01 level; 
between the M 50 and M 90 for two different design mechanisms for the 
pumps, on three different · spray angles and the M 50 for the threes sizes of 
spray inserts. However the M9o for the 0.7 mm orifice insert was found to be 
significantly different from 0.1 mm and 0.3 mm. 
The actuator and orifice diameter of the spray insert of metered nasal spray 
pump that were designed to be able to facilitate breakdown of the higher 
viscosity formulations from a stream to fine spray did not produce any 
significant differences in the droplet size distributions. This study emphasized 
the need to explore the effect of increased pressure on the higher viscosity 
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FIGURE 11 THE INFLUENCE OF SPRAY ANGLE ON THE DROPLET SIZE DISTRIBUTION 
USING METERED NASAL SPRAY PUMP 
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FIGURE 10 I Ht: INt-LUENCE OF ORIFICE DIAMETER ON THE DROPLET SIZE 
DISTRIBUTION FOR METERED NASAL SPRAY PUMP 
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formulations. It was decided to evaluate the prototype nasal micron spray 
pump. 
Nasal micron spray pump 
The nasal micron spray pump (NMSP) is a prototype device designed to 
reduce the particle size distribution by using the increased pressure generated 
by the of air blast nozzle. Since viscosity seemed to be the most influential 
factor in the determi na tion of droplet size, the formulat ions varying in 
viscosity were delivered using this new prototype spray pump and droplet 
size determined. The NMSP was able generate a Mso of 53.27±3.38 µm and a 
Mgo of 223.44±83.44 µm for a 1 cps buffer and also to deliver the 11.35 cps 
(0.5%w /w) and 76 cps (1 % w /w) methylcellulose formulations with an 
average Mso of 54.25 µm and 112.45 µm respectively (figure 12). These same 
formulations when delivered with the standard metered spray pump 
measured Mso of 105.86 µm for 0.5% w /w methylcellulose of 11.35 cps and a 
Mgo of 382.38±45.82 µm. Thus nasal micron spray pump was able to reduce 
the average droplet size distribution for high viscosity solutions significantly. 
However the spray profile for the NMSP showed a bimodal curve which 
seems to be due to a portion of spray striking the mouthpiece upon release 
from the air blast nozzle. Interestestingly the NMSP delivered the 76 cps 
solution formulation as a fine spray, but could not disperse solutions having 
higher viscosity than 76 cps as a fine spray. Neverthless thos prototype spray 
device seems to have the potential of provideing more "narrowed " spray 
distribution for high viscosity formulations . 
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FIGURE 12 THE INFLUENCE OF VISCOSITY ON THE DROPLET SIZE DISTRIBUTION 
USING NASAL MICRON SPRAY PUMP 
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The influence of formulation variables and devices on nasal drug delivery 
has been focus of many investigations. However there is no published 
information on how the different components of nasal spray pump can affect 
the spray characteristics and the droplet size. In this study an attempt was 
made to determine the influence of nasal administration device v ariables, 
such as design mechanism of the pumps, actuator, spray insert diameter as 
well as the various formulation parameters such as viscosity and presence of 
absorption enhancer on the droplet size parameters Mso and M9o. However 
the influence of these spray profile on bioavailability is not known and is yet 
to be elucidated. 
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MANUSCRIPT II 
THE INFLUENCE OF TONICITY AND VISCOSITY ON THE INTRANASAL 
BIOA V AILABILITY OF SALMON CALCITONIN IN RABBITS. 
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ABSTRACT 
As with any drug delivery system, a clear understanding of the 
physicochemical and formulation factors is necessary for rational design of 
the dosage form. Formulation factors require careful assessment to identify 
those which may influence pharmacological or physiological response and 
thus assure optimum therapeutic activity. On the basis of physicochemical 
and biopharmaceutical studies of peptide or protein drugs; a nasal 
formulation administered with an appropriate delivery device may be 
designed to provide optimal nasal activity. In the present study an attempt 
was made to investigate the effect of tonicity and viscosity on the intranasal 
absorption of salmon calcitonin (sCT). Formulations were designed as nasal 
sprays with a viscosity of 1 or 76 cps, using 0% w /w and 1 % w /w 
methylcellulose as the viscosity enhancing agent; and with a tonicity of 100, 
300 or 600 mOsms, using sodium chloride as the tonicity adjusting agent to 
provide hypotonic, isotonic and hypertonic formulations . Chlorbutanol was 
used as a preservative. The low viscosity formulations were delivered using a 
metered nasal spray pump and the high viscosity formulations were 
administered using a prototype device, the nasal micron spray pump, to 
facilitate a uniform distribution of the spray into the nasal cavity. Serum 
levels of sCT were determined in healthy male New Zealand rabbits after 
intranasal administration of 2000 IU of sCT in 200 µl. The pharmacodynamic 
effect of salmon calcitonin of lowering blood calcium level was determined by 
a visible spectrophotometric technique. A full factorial design was employed 
with ANOVA and Scheffe's multiple comparison test used to analyze the 
data. Deviation from isotonicity was found to increase the bioavailability by 4-
5 times . Variation in the viscosity did not influence the bioavailability of 
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salmon calcitonin. Response surface methodology and the canonical analysis 
parameters were applied to determine the optimum formulations. 
Key Words: Calcitonin, Intranasal, Tonicity, Viscosity, Methylcellulose, Nasal 
spray, Osteoporosis, Spray pumps. 
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INmODUCTION 
The recent phenomenal advancement in biotechnology has contrived 
stimulating opportunities for the use of peptides and proteins as novel 
therapeutic agents. The emergence of these peptides and proteins has raised 
questions as to the extent to which existing formulation and drug delivery 
technologies can be used and the type of new technologies that must be 
developed to ensure the maximum therapeutic activity. Peptides and proteins 
have been administered intravenously because of the low oral bioavailability. 
This is very inconvenient for patients suffering from chronic diseases. 
Therefore, the administration of peptides and proteins by way of the mucosal 
routes such as nasal, rectal, buccal, vaginal and ocular mucosae are being 
investigatedl . 
The use of the intranasal route for systemic delivery of peptide and protein 
drugs has several potential advantages including the large surface area of the 
nasal cavity and the highly vascularized nature of nasal mucosa. Nasal 
absorption of polypeptides such as oxytocin2, synthetic lysine vasopressin3, 
synthetic LH-RH and its analogues4, insulinS-7, enkephalins analogs8, 
growth hormone releasing factor9-10 has been reported. The permeability of 
the nasal mucosa to peptides seems to decrease with increasing molecular 
weight. For peptides with a molecular weight of more than lOOOD, 
bioavailabilities are in the range of 1-3%11-12. The nasal absorption efficiency 
of peptides and proteins is also influenced by the overall design of the dosage 
form as well as the devices used for administration. Some of the dosage forms 
which have been investigated are solutions13-14 gelslS, powders16 and 
microspheres17. These dosage forms have been used for the administration of 
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insulinlS-20, human growth hormone21-22, oxytocin23, desmopressin24 and 
propranolol25. The earliest and the most classical form of nasal formulation 
is the solution. However solutions have often been shown to provide lower 
bioavailability because they are more readily cleared from the nasal cavity, 
particularly when administered as drops. Conversely sprays are confined to 
the nonciliated regions of the nasal cavity and therefore are retained longer 
than drops26. There is little information on how the formulation variables of 
a nasal spray such as buffer concentration, buffer species, ionization of buffer 
species, ionic strength, viscosity, charge, pH of vehicle, osmolarity, type and 
concentration of preservatives could further influence the absorption of 
peptide and proteins. 
Salmon Calcitonin, a polypeptide hormone secreted by the parafollicular C 
cells of the thyroid gland, lowers serum calcium levels by decreasing bone 
and renal tubular reabsorption of calcium. Injectable formulations of salmon 
calcitonin have been used with some success in the management of metabolic 
bone disorders such as osteoporosis and Paget's disease but this form of 
administration is inconvenient and has been poorly tolerated by the patients. 
The development of an intranasal preparation of salmon cakitonin will 
provide a more convenient means of administering the drug27. Intranasal 
spray preparations conta_ining salmon calcitonin have been shown to be 
effective in metabolic bone disease28 . Unfortunately nasal bioavailability is 
significantly lower than that realized by injection. Salmon calcitonin in a 
spray form is now registered in some European countries, however a nasal 
spray of salmon calcitonin has not been approved in United States by FDA as 
yet. The available data indicate a reasonable absorption, but there is very little 
detail addressing the effects of formulation parameters, such as pH, ionization 
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of buffer salts, osmolarity, viscosity, etc., on the bioavailability29-30. To 
optimize drug activity, the factors influencing the drug, formulation 
components in combination with delivery devices must be identified and 
modified to realize significant drug activity. 
Since the stability of calcitonin dictates such parameters as pH, buffer and 
preservatives; this study was designed to investigate the effect of the 
formulation variables, viscosity and tonicity, on the intranasal bioavailability 
of salmon calcitonin. Previous studies have been carried out with various 
drugs to evaluate the effects resulting from an increase in viscosity in a 
formulation. An increase in viscosity is postulated to increase the particle size 
of a spray formulation which leads to a more localized deposition and slower 
clearance from nose . However, the effects of increased viscosity on 
mucociliary clearance, are difficult to interpret. According to some authors, an 
increase in viscosity results in a decrease in the clearance rate31. 41 other cases 
a progressive increase in viscosity leads to an initial slowdown of clearance 
followed by an increase32. Increasing viscosity also seems to progressively 
lower the rate of diffusion· of the drug from the deposited droplets resulting 
in delayed release and absorption without improvement in bioavailability. 
While the above data was generated using viscosity in the range of 1-11 cps, 
the present study will investigate the use of a significantly higher viscosity (-
75 cps) formulation obtained by using 1 % w /w methylcellulose. Previous 
studies have shown that metered nasal spray pumps are limited in their 
ability to spray higher viscosity solutions as a fine spray. It has been shown 
that at is not possible to achieve a gaussian droplet size distribution for 
solutions of viscosity greater than 2.12 cps33. However high viscosity 
for~ulations can be delivered as a fine spray using a prototype device, the 
63 
( 
( 
nasal micron spray pump, to facilitate the uniform distribution of spray in the 
nasal cavity. These results will be compared to those obtained using a low 
viscosity formulation, 1 cps, delivered from a commercially available metered 
dose spray pump. Additionally, the study will compare the droplet size 
distribution obtained with the two different devices, the effect on Tmax, the 
time required to obtain maximum concentration in the blood, and the 
bioavailability of salmon calcitonin. 
Isotonic solutions are used to assist cells in maintaining a stable physiological 
environment. Deviation from isotonic conditions can cause tissue damage, 
irritation, hemolysis of blood cells and electrolyte imbalance. However very 
little information has been generated on the effect of varying the degree of 
tonicity for oral or mucosal drug delivery especially intrari.asal formulations. 
Absorption of quinine from the small intestine was found to decrease with 
increasing hypertonicity34 . Malone et al, 1960, reported that the oral 
absorption of phenobarbitone in the rat was higher from hypotonic than from 
hypertonic solutions35. However Ohwaki et al, 198436, demonstrated an 
increase in the bioavailability of secretin from the nasal cavity with 
hypertonicity. Based on the information obtained from these few 
experiments, it is difficult to interpret the effect of tonicity on the absorption 
in the nasal cavity. The literature does not cite any reference of the effect of 
tonicity on the bioavailability of salmon calcitonin. This study investigates 
the effect of tonicity at three levels, isotonicity (300 mOsm), hypotonicity (100 
mOsm) and hypertonicity (600 mOsm). These formulations were obtained by 
using sodium chloride as tonicity adjusting agent. Since the formulation is 
meant for a chronic use, mild deviations from isotonic conditions was 
investigated as severe deviation can effect the integrity of the nasal mucosa. 
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EXPERIMENTAL 
Materials 
Salmon calcitonin (sp. activity 5384 I.U./mg) was a gift from Armour 
Pharmaceuticals, Kankanee, IL). RIA Kits were procured from (Diagnostics 
Systems laboratories, Webster, TX), Acetic acid and sodium acetate, analytical 
grade were purchased from (Fisher Scientific, Fair Lawn, NJ). The anesthetics, 
acepopromazine maleate, ketamine hydrochloride (Aveco Co. Inc., Fort 
Dodge, IA), DMA Calcium Plus Reagent® (DMA, Houston, TX), 
Methylcellulose, Methocel A15C (Dow Chemical Company, Midland, Ml), 
Chlorbutanol (Sigma Chemical Company, St. Louis, MO), Catheters and 
Serum separators (Baxter Health Care Corporation, Deerfield, IL), Heparin 
Sodium injection, USP (Elkins-Sinn Inc., Cherry Hill, NJ) were purchased and 
used as received. Distilled water was used in all nasal formulations . 
A 50 µl metered nasal spray pump was chosen to deliver the low viscosity 
formulations (1 cps). A prototype device, the nasal micron spray pump 
(NMSP), capable of spraying 35 µl per actuation was employed to deliver 
formulations of higher viscosity (76 cps). Both the pumps were provided by 
Pfeiffer GMBH, Radolfzell, Germany. 
Methods 
Preparations of formulations 
The formulations were prepared with a concentration of methylcellulose 
ranging from 0% to 1 % w /win a 0.03 M sodium acetate-acetic acid buffer at pH 
4 and kept in the refrigerator. A pH of 4 was selected for the formulation as 
salmon calcitonin has maximum stability between pH 3-5. The formulation 
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was refrigerated as salmon calcitonin has been reported to be most stable when 
stored at 2-40C. 
Measurement of the osmotic pressure (tonicity) 
The osmotic pressure of the formulations was measured using a A-010 
Microdiagnostics Osmometer. Standards were measured ranging from 100 
mOsm-2000 mOsm and then formulations were measured in duplicate. 
Administration of nasal formulations to the rabbits 
It has been shown37 tha t differences in volume, concentration, or dosing 
technique for an intranasal drug can provide a significant difference in 
bioavailability. Instilling a drug as a smaller volume in both nostrils as 
compared to a larger volume in one nostril demonstrated a lower coefficent of 
variation and slower clearance from the nose. 
It has been demonstrated38 that the addition of a viscosity enhancing agent 
increases the contact time of the dosage form to the mucosa! membrane and 
may help to enhance the absorption by reducing the clearance of the 
administered drug. Viscosity also changes the pattern of deposition and 
clearance38. In these studies the viscosity used was in the range of 1-3.5 cps, 
which can be considered as low viscosity solutions. The NMSP, a prototype 
device originally developed for inhalation solution was investigated for its 
ability to deliver higher viscosity solutions as a fine spray. The lower droplet 
size distribution for the high viscosity solutions is achieved by the NMSP 
using an air blast nozzle as an actuator." By improving the geometry and 
therefore the dynamic properties within the spray nozzle, the droplet 
spectrum has been reduced to smaller diameters leaving the spray nozzle39. 
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A standard metered manual spray pump was chosen to deliver low viscosity 
formulations (1 cps). A metered 50 µI nasal spray pump based on a ball and 
spring mechanism was combined with a flanged actuator using a spray insert 
with a 35° spray angle was used. The total volume of 200 µl to contain the 
dose was instilled by spraying twice into each nostril. The NMSP was 
employed to deliver formulations of higher viscosity (76 cps). The volume 
delivered was 35 µl per actuation and a 210 µl volume to contain the dose was 
instilled by spraying 3 times into each nostril. 
In vivo study 
Animal Model 
The New Zealand white rabbit was selected as an animal model because it 
provides a well controlled animal model for screening the nasal absorption 
potential of sprayed drug formulations. The blood volume of the rabbit is 
sufficiently large to permit frequent blood samples and allow a full 
characterization of the absorption profile of the drug40. Rabbits were obtained 
from Milbrook farms (Amherst, MA) with a mean weight of about 3 kg. The 
study protocol was reviewed and approved by the Institutional Animal Care 
and Use Committee, University of Rhode Island, Kingston, RI 
Experimental procedure 
The rabbits were fasted for 36 hours prior to each experiment with free access 
to water. The rabbits were anesthetized with an i.m. dose of 0.25 mg/kg of 
ketamine hydrochloride and 2.5 mg/kg of acepopromazine maleate. Rabbits 
were kept lying on their backs on thermal rugs during each experiment. A 
catheter was placed in the rabbit's median ear artery and a 0.8-1 ml blood 
sample was collected at -5, 10, 20, 30, 40, 50, 60, 75, 90, 120, 180, 240 and 300 
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minutes after administration of the formulation. The samples were allowed 
to clot for at least 30 minutes at room temperature and then centrifuged at 
3000 rpm for 10 minutes and stored at -2ooc until assayed . 
The control group was used to measure any interference from the trauma of 
administration of anesthesia on the inherent calcitonin level. The control 
rabbits were subjected to the same conditions, however calcitonin was not 
administered. The values obtained were subtracted from the levels obtained 
after administration of calcitonin formulations. 
Study Design 
Calcitonin was administered as spray to the rabbits as per a randomized cross -
over design. A wash out period of at least one week was allowed between 
treatments . 
Analytical methods 
Serum calcitonin 
All serum samples were assayed with a commercial RIA kit developed at 
Diagnostics Systems Labortories (Webster, TX). Guinea pig anti-sCT antibodies 
were used as primary antibodies and have demonstrated less than 2% w /w 
cross reactivity. The sigmoidal standard curve of B/Bo vs [sCT], typical of 
competitive binding assays was linearized using the log transformation. The 
best fit line was determined using a non weighted least square regression 
analysis. The radioimmunoassay quantitation range was 100-5000 pg/ml. The 
square of the coefficent of determination (r2) in this range for the B/Bo versus 
log[sCT] plots was greater than 0.993 for all assays performed in duplicate. 
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Serum calcium levels 
Serum calcium levels were determined using a DMA Calcium Plus 
Procedure® utilizing arsenazo III to bind the calcium at an acid pH and form 
a bluish purple complex. Ser um calcium was quantified 
spectrophotometrically at 650 nm and the range of the linearity was 
determined to be between 5-25 mg/ dl. The square of the correlation (r2) in this 
range for the absorbance versus concentration (mg/ dl) was 0.999 for all the 
assays performed in duplicate during the course of study. 
Data Analysis 
The concentration of calcitonin was measured in the serum over a period of 5 
hours after administration · of salmon calcitonin formulations. Salmon 
calcitonin activity was determined as a function of lowering of calcium levels. 
The nasal bioavailability of calcitonin was calculated relative to the serum 
calcitonin levels over a period of 5 hours after injecting calcitonin 
intravenously. Cmax values are the peak serum calcitonin concentrations 
observed at time Tmax after adminstration of calcitonin. 
%Absolute Bioavailability = AUCin-AUCcontrol x Doseiv x 100 
AUCiv-AUCcontrol Dosein 
The hypocalcemic effect was measured in terms of maximal decrease (%maxd) 
which was calculated as the highest percentage of reduction in calcium levels 
as compared to the basal values. The total decrease in serum calcium level 
(D%) was calculated using a modified method, by Hirai et al, 198141. 
D% = AUCcontrol-AUCin X JOO AUCcontrol 
69 
( 
( 
where AUCin, AUCcontrol and AUCiv refer to the area under the curve 
calculated by the linear trapezoidal rule. AUCin refers to area under the curve 
calculated after the intranasal administration of calcitonin formulations. 
A UC iv refers to area under the curve calculated after the intravenous 
administration of cakitonin formulations. AUCcontrol refers to area under the 
curve calculated without administration of the cakitonin. The time at which 
this reduction takes place is T max. 
The data was analyzed by ANOVA using Statistical Analytical Software (SAS). 
The formulation effects were compared with the controls using Dunnett's 
test. Multiple comparison among the treatment effects were determined 
using Fisher's Least Significant Difference test (LSD) and/ or Scheff e's 
multiple comparison test. Differences among the treatments were assumed 
to be significant for values of p < 0.05. 
Determination of optimum formulations 
One of the main objectives of this investigation was to study the effects of 
tonicity and viscosity on the intranasal bioavailability. Tonicity was 
investigated at 3 levels of 100, 300 and 600 mOsm and viscosity was studied at 
two levels of 1 and 76 cps. In order to optimize the effects of the independent 
variables of viscosity and tonicity on the dependent factor, area under the 
curve, a full factorial statistical design, was used. A factorial design was used 
to study the primary effects of viscosity and tonicity and the secondary effects 
or interactions of viscosity and tonicity on the intranasal absorption of sCT 
In the simplest of cases, techniques used for optimization involve the 
determination of maximum or minima but when the relationship for the 
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response is given as a function of two or more than two independent 
variables, the system becomes more complicated . In the present case, 
Response surface methodology (RSM) was applied to estimate the maximum 
or minimum response so as to determine the optimum formulations for the 
nasal delivery of salmon calcitonin. The SAS/RSREG software was used to fit 
the parameters of the complete quadratic reponse surface obtained from the 
three levels of tonicity incorporated in the formulations. The fitted surface 
was analyzed to determine the level of the independent variable providing 
the optimum response. The predicted optimal value can be found from the 
estimated surface, which usually shows a minima, maxima or saddle point, if 
there is no clear maxima or minima. Since the independent variable should 
be at three or more levels, tonicity was designated an independent variable 
with area under the curve as a response surface. Viscosity was used as a 
covariate that was investigated at two levels.42 
RES UL TS AND DISCUSSION 
(A) Intravenous administration 
The average serum sCT concentration versus time profile for 5 l.U. of i.v. 
administered dose is shown in figure 1. The average Cmax was 25±2.9 ng/ml 
at a Tmax of 14±2.4 minutes and the area under the curve (AUC) was 
1102.1±19.8 ng.min/ml as compared to control group in which average 
concentration was 2 ng/ml and the AUC was 401±75.3 ng.min/ml. The 
salmon calcitonin levels obtained in the serum were significantly different 
from the control level at p< 0.05. The pharmacokinetic parameters are 
simmarized in Table I. 
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FIGURE 1 CONCENTRATION TIME PROFILE OF SALMON 
CALCITONIN AFTER IV ADMINISTRATION (N=5); DOSE 5 IU 
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TABLE I PHARMACOKINETIC PARAMETERS AFTER INTRANASAL ADMINISTRATION 
OF SALMON CALCITQNIN TO NEW ZEALAND RABBITS (N = 5) 
VARIABLE Tmax (min) Cmax(nglml) AUC(ng.min/ml) % Bioavailability 
CONTROL 401 ± 75.3 
I.V (5 I.U.) 14 25 ± 2.9 1102.1 ± 19.8a 100 
INTRANASAL 
LOW VISCOSITY 
DOSE 2000 I.U. 
ISOTONIC 40 10 ± 4.2 ...l. 714.2 ± 15.7 0.16 
HYPERTONIC 90 42±19.6 3508±1280b 0.80 
HYPOTONIC 38 26 ± 7.6 3171±25sb 0.71 
INTRANASAL 
HIGH VIS~QSII~ 
DOSE 2000 I.U. 
ISOTONIC 58 12 ± 9.7 604.6 ± 97.74 0.14 
HYPERTONIC 90 32±19.6 2183 ± 258b 0.62 
HYPOTONIC 120 23±2.4 3579±1030b 0.81 
a significantly different from control at p<0.05 
b significantly different at low and high viscosity at p<0.5 
,,--..., 
The pharmacodynamic effect of sCT of lowering calcium is shown in figure 2 
and summarized in Table II. The total reduction in calcium level is termed as 
D%. The hypocalcemic effect is also ~easured in terms of maximal percent 
decrease (%maxd)· which is the highest percent of reduction in calcium levels 
as compared to the basal values. The time at which this reduction takes place 
is Tmax. However between D% and %maxd; the 0 % is considered to be a 
more acceptable measure of hypocalcemic activity as it encompasses the 
overall reduction in activity rather than reduction at one time point. 
It can be seen that the administration of the 5 IU iv dose resulted in a initial 
percent maxim~l decrease (%maxd) of 28% of calcium at 30 minutes (Tmax) · 
After 30 minutes there was an increase in the calcium level, and then there 
was a grad ual decrease after 75 minutes until 240 minutes. This pattern of 
concentration change may be explained on the basis that often administration 
of salmon calcitonin, there is a decrease in the calcium level, once the 
calcium level reaches a critical value, the parathyroid hormone already 
present in the body counteracts the effects of calcitonin and raises the calcium 
level. Thus the total lowering, 0 %, was calculated and was found to be 32% as 
compared to the control group. The AUC for i.v . administration was 
2732±271.39 mg.min/ dL as compared to the AUC for the control group of 
4045.40±255.17 mg.min/dL and was significantly different at p<0.05. 
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TABLE II PHARMACODYNAMIC PARAMETERS AFTER INTRANASAL ADMINISTRATION 
OF SALMON CALCITONIN TO NEW ZEALAND RABBITS (N =5); DOSE 2000 IU 
VARIABLE Tmax{min} • Mil.Q.1%1 AUC {mg.min/g1} %0 
CONTROL 4045.40 ± 255.1 7 
I.V (5 IU) 30 28 2732 ± 271.39a 32 
LQW VISCQSITY 
ISOTONIC 240 12.96 3724.12± 120.99 7.9 
HYPERTONIC 75 28.83 3267.74 ± 31.31 a, b 19 
HYPOTONIC 180 28.12 3308.0 ± 42.45a 18 
HigH VISCOSITY 
ISOTONIC 240 28.81 ' 3242.83 ± 21.66 19 
HYPERTONIC 90 23.52 3696.28 ± 53.24a, b 9.0 
HYPOTONIC 120 34.58 3154.47 ± 102.49a 22 
a= significantly different from control at p<0.05 
b =signi ficantly different at low and high viscosity p< 0.05 
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FIGURE 2 THE INFLUENCE OF IV ADMINISTRATION OF 
SALMON CALCITONIN ON THE CA LCIUM LEVEL (N=S) 
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(B) Intranasal administration 
Effect of tonicity with varying viscosity 
Influence of isotonicity 
To determine the effect of tonicity on the absorption of salmon calcitonin, the 
base formulations containing a dose of 2000 IU salmon calcitonin in a isotonic 
0.03 M acetate buffer at a pH 4 with a viscosity of 1 cps were administered to 
the rabbits. The AUC, Cmax, Tmax and bioavailability of all the formulations 
differing in tonicity are summarized in table I. The AUC of isotonic 
formulations at a viscosity of lcps w as 714 .2±15.7 ng.min/ml with a 
bioavailability of 0.16. The Cmax obtained by the formulations was 10±4.2 
ng/ml at a Tmax of 40 minutes. 
In contrast higher viscosity (76 cps) isotonic (300m0sm) formulations were 
prepared with 1 % methylcellulose at pH 4 containing 2000 IU salmon 
calcitonin in 200 µl sprayed into the nasal cavity of rabbits elicited a Cmax of 
12±9.7 ng/ml at a Tmax of 58±8.3 minutes as shown in figure 3. The AUC for 
the higher viscosity isoton·ic formulations was 604.6±97.74 ng.min/ml with a 
bioavailability of 0.14. There was no significant difference in the low and high 
viscosity formulations at isotonic conditions. 
The bioavailabili ty obtained by the intranasal administration of salmon 
calcitonin for low and high viscosity isotonic formulations was extremely low 
and is typical of higher molecular weight polypeptides as shown by previous 
investigatorsll. 
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FIGURE 3 THE INFLUENCE OF VISCOSITY ON THE 
INTRANASAL ABSORPTION OF SALMON CALCJTONJN 
IN ISOTONIC SOLUTIONS 
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Influence of hypertonicity 
The low viscosity hypertonic (600m0sm) formulations sprayed intranasally 
showed a Cmax of 42±19.6 ng/ml at Tmax of 90±12 minutes as shown in 
figure 4, as compared to a Cmax of 10±4.2 ng/ml at a Tmax of 40 minutes for 
low viscosity isotonic (300m0sm) formulations . Thus deviation from 
isotonicity elicited a higher concentration of sCT in the serum at a low 
viscosity of 1 cps. The AUC calculated for low viscosity hypertonic salmon 
calcitonin formulations was 3508±1280 ng.min/ml with a bioavailability of 
0.80. The bioavailability obtained was about five times higher than that 
obtained for low viscosity isotonic formulations . 
The higher viscosity (76 cps) hypertonic (600m0sm) formulations prepared 
with 1 % methylcellulose and sprayed into the nasal cavity of rabbits elicited a 
Cmax of 32±19.6 ng/ml at Tmax at 90±12 minutes as shown in figure 4. The 
area under the curve was 2183± 258 ng.min/ml with a bioavailability of 0.62. 
Thus deviation from isotonicity at a higher viscosity also demonstrated an 
increased level of salmon calcitonin in the serum. The bioavailability 
obtained by high viscosity hypertonic salmon cakitonin formulations was 
significantly different from high viscosity isotonic formulations as 
determined at p<0.05 
Influence of hypotonicity 
The low viscosity (lcps) hypotonic (100m0sm) formulations in an acetate 
buffer at pH 4 when sprayed into the nasal cavity of rabbits produced a Cmax 
of 26±7.6 ng/ml at Tmax of 38±9.16 minutes as shown in figure 5. The AUC 
obtained was 3171.33±258 ng.min/ml with a bioavailability of 0.71. The AUC 
obtained for low viscosity hypotonic formulations was almost of the same 
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FIGURE 4 THE INFLUENCE OF VISCOSITY ON TH E 
INTRANASAL ADSORPTI ON OF SALMON CALCITONJN 
IN HYPERTONIC SOLUT IONS 
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FIGURE 5 TllE INFLUENCE OF VISCOSITY ON THE 
INTRANASAL ABSORPTION OF SALMON CA LC ITONIN 
FOR HYPOTONIC SOLUTlONS 
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magnitude as low viscosity hypertonic formulations and was significantly 
different from low viscosity isotonic formulations at p<0.05. 
The higher viscosity hypotonic (lOOmOsm) for mulations prepared with 1 % 
methylcellulose at a pH of 4 when sprayed into the nasal cavity of rabbits 
produced a Cmax of 23±2.4 ng/ml at Tmax of 120±18 minutes respectively. 
The AUC calculated was 3579±1030 ng/ml with a bioavailability of 0.81. Even 
at high viscosity, a deviation from isotonicity produced an increase in the 
bioavailability. 
Thus, it can be seen that absorption of hypertonic and hypotonic formulations 
was significantly different from isotonic formulations at both low and high 
viscosity and bioavailability of the drug was enhanced in both the hypotonic 
and hypertonic conditions by approximately 4-5 fold . 
There have been very few experiments performed to study the effect of 
tonicity, but the information generated from these studies indicates that 
deviation from the tonidty influences the absorption and this could be 
explained by the fact that the hypertonic solutions cause shrinkage of the cells 
and hypotonic solutions cause swelling of the epithelial cells as a result of 
increased water uptake which could alter the pore size within the cell 
junctions and the permeability of the cell walls thus leading to enhanced 
absorption43. 
Influence of viscosity 
It can be seen from the literature that low and high viscosity (1-11 cps) 
formulations when administered using a metered nasal spray pump that the 
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ability of this pump to produce a fine uniform spray is limited for high 
viscosity formulations. Therefore, in this study a metered dose spray pump 
based on a ball and spring mechanism was used to spray low viscosity (lcps) 
formula tions and a nasal micron spray pump (NMSP) designed with a air 
blast spray nozzle was used to spray higher viscosity (76 cps) formulations. 
The droplet size d istribution generated by both the devices had been 
previously measured using a Malvern sizer and categorized as Mso which is 
the droplet size of 50% of the droplets sprayed33. 
The average Mso droplet size for formulations with a viscosity of 1 cps was 
45±1.llµm and the droplet size Mso of formulations of viscosity, 76 cps was 
112.48±27.6 µm when sprayed using a metered dose spray pump33. The M50 
generated by the NMSP was 53.27±3.38 µm for the 1 cps and 112.45±27.6 µm 
for the 76 cps formulations. The M50 generated by two nasal delivery devices 
for the formulations differing in viscosity by 76 cps was approximately 
different by 2.5 fold (45 µm vs 112.45 µm) . Thus nasal micron spray pump was 
very successful in lowering the average droplet size as well as reducing the 
range of the droplet size distribution. Interestingly, the distribution produced 
by metered nasal spray pump for 1 cps viscosity was Gaussian and unimodal 
while that produced by NMSP deviated slightly from Gaussian behavior and 
was bimodal33. 
The Tmax produced b y the low viscosity isotonic and hypertonic 
formulations was 40 and 38 minutes respectively as compared to that for the 
higher viscosity isotonic and hypertonic formulations of 58 and 120 minutes 
which agrees with literature that postulates that a higher droplet size leads to 
a more localized deposition and causes a slower clearance from the nose32. 
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However for the hypertonic formulations, the Tmax for both low viscosity 
and high viscosity formulations was 90 minutes. A possible explanation may 
be that the Tmax is not only a measure of higher viscosity but also is affected 
b the other excipients of the formulation, especially the tonicity adjusting 
agent, sodium chloride which could change the time required to achieve the 
maximum concentration by altering the physiological and pharmacological 
response generated by the formulation in the surrounding enviornment. 
There was a decrease in the absorption of sCT from higher viscosity isotonic 
and hypertonic formulations. Similiar results have been reported by Harris, 
198932 who used methylcellulose as a viscosity enhancing agent and 
demonstrated no improvement in the bioavailability of the drug and actually 
reported a decrease in absorption possibly due to the delayed diffusion of drug 
from the formulation because of the higher viscosity. Variation in the 
viscosity did not show any significant difference in the absorption of sCT. 
Pharmacodynamic effects · 
Effect of tonicity with varying viscosity 
Influence of Isotoncity 
The pharmacodynamic effect of sCT of the lowering of calcium for all the 
formulations varying in tonicity as a function of viscosity were calculated and 
are summarized in table II and shown in figures 6-8. The AUC for isotonic 
formulations at low viscosity was found to be 3724.12±120.99 mg.min/dL as 
compared to 4045±255.17 mg.min/dL for the control group and 2732±271.39 
mg.min/ dL for i.v administration. Isotonic low viscosity formulations 
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FIGURE 6 THE INFLUENCE OF VISCOSITY ON THE 
CALCIUM LEVEL AFTER INTRANASAL ADMINISTRATION 
OF ISOTONIC SALMON CALCITONIN SOLUTIONS 
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sprayed intranasally were able to produce a red uction in calcium activity (D%) 
of 7.9% and a maximum reduction, (%maxd), of 12.96 at a Tmax of 240 
minutes. However the low viscosity isotonic formulations were not able to 
produce a significant difference as compared to the control group at p<0.05. 
The AUC for the high viscosity isotonic formulations was 3242.83±21.66 
mg.min/ dL and produced a total reduction in activity of 19% and a 
maximum reduction of 28.81 at a Tmax of 240 minutes. There was an initial 
maximal decrease at 60 minutes and the level of calcium started rising from 
60 minutes until 90 minutes and again there was a gradual decrease until 240 
minutes. The maximal percent decrease for the low and high viscosity 
isotonic formulations was obtained at 240 minutes as seen in figure 6.The 
high viscosity isotonic formulations generated a significant difference as 
compared to the control and low viscosity isotonic formulations. This may be 
due to the slower clearance that is postulated for higher viscosity 
formulations have longer contact with the mucosa! membrane. The calcium 
lowering effect for high viscosity isotonic formulations was significantly 
different from low viscosity isotonic formulations and control group. 
Influence of hypertonicity 
The AUC for the low viscosity hypertonic formulations was 3267.74±31.31 
mg.min/ dL as compared 4045±255.17 mg.min/ dL for the control group. These 
hypertonic formulations at low viscosity when sprayed intranasally were able 
to produce a total reduction in calcium activity (D%) of 19% and a maximl1m 
reduction, %maxd, of 28.83 at a Tmax of 75 minutes. The total calcium 
lowering effect of low viscosity hypertonic formulations was almost 2.5 times 
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FIGURE 7 THE INFLUENCE OF VISCOSITY ON THE 
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more than low viscosity isotonic formulations and was also significantly 
different from control group. 
The AUC for high viscosity hypertonic for m ulations was 3696.28±53.24 
mg.m in /dl. and when sprayed in tranasally w ere able to produce a total 
reduction attivity of 9% and a maximum reduction of 23.52 at a Tmax of 90 
minutes . The calcium lowering effect for high viscosity formulations was 
significantly different from low viscosity formulations and was more 
comparable to the low viscosity isotonic formulations . The difference in the 
pattern of low and high viscosity hypertonic formulations on the calcium 
lowering effect is not known. 
Influence of hypotonicity 
The AUC for the low viscosity hypotonic formulations was 3308±42.45 
mg.min/ dL and produced a total reduction in calcium activity of 18% and a 
maximum reduction of 28.12% at a Tmax of 180 minutes as seen in figure 8 .. 
The calcium lowering effect produced by low viscosity hypotonic 
formulations was comparable to that produced by low viscosity hypertonic 
formulations and was significantly different from controls. 
The AUC for high viscosity hypotonic formulations was 3154.47±102.49 
mg.min/dL produced a total reduction in activity of 22% and a maximum 
reduction of 34.58 at a Tmax of 120 minutes. The calcium lowering effect of 
the high viscosity hypotonic formulations was also similiar to low viscosity 
hypotonic formulations and significantly different from the low viscosity 
isotonic and control formulations. 
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FIGURE 8 THE INFLUENCE OF VISCOSITY ON THE CALCIUM 
LEVEL AFTER INTRANASAL ADMINISTRATION OF SALMON 
CALCITONJN HYPOTONIC SOLUTIONS 
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The %maxd of 28.83% produced by low viscosity hypertonic formulations (600 
mOsm) and 28.12% produced by low viscosity hypotonic formulations (100 
mOsm) was comparable to 0/..)maxd produced by i.v. administration of 28%. 
However the total reduction in activity (O'X.) for the iv formulations were 
significantly greater than that seen after nasal administration. 
The lowering of calcium for all formulations ranged from 7.9 to 22% of the 
basal value in intranasal formulations as compared to 32% for the iv 
solutions . The %maxd intranasal delivery ranged from 12 to 34.5% as 
compared to 28% in iv administration. The similarity of the extent of the 
hypocalcemic effect observed after administration of different intranasal 
formulations of sCT may be attributed to the acute homeostatic mechanism 
between cakitonin and the parathyroid hormone. The parathyroid hormone 
counteracts the effects of calcitonin once a critical level of hypocakemia is 
attained. Thus the extent of the hypocalcemic effect is controlled by the 
hormonal balance. The acute control of blood calcium is accomplished by the 
feedback action of calcitonin and the parathyroid hormone. This complex 
regulation of blood calcium concentration makes it difficult to evaluate the 
efficacy of sCT delivery systems by observation of the hypocakemic effect44. 
Although the measure of pharmacodynamic effects is useful clinically 
especially in the event of low bioavailability, the results obtained from the 
various biochemical markers for salmon ca lei tonin such as lowering in 
calcium, bone turnover and decrease in the urinary hydroxyproline are 
difficult to interpret as these parameters are also under hormonal regulation 
and may or may not differ for healthy subjects and diseased subjects. 
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It has been demonstrated that the hypocalcemic effect of intranasal salmon 
calcitonin is governed by the underlying rate of bone turnover and therefore 
the effect is minimal in healthy volunteers. That is healthy subjects do not 
show a significant change in bone turnover w hile a more pronounced action 
is observed in subjects with active osteoporosis or Paget's d isease45. 
On the other hand , quantitatively similiar reductions in urinary 
hydroxyproline excretion were demons trated, indicating similiar levels of 
inhibition of osteoclastic bone resorption following intranasal administration 
of 200 to 400 IU salmon calci tonin in healthy volunteers aged less than 30 
years and elderly patients w ith osteoporosis or Paget's disease46. 
Since the hypocalcemic effects of calcitonin are governed by the underlying 
rate of bone turnover, the pharmacokinetic parameters which relate to the 
presence of salmon calcitonin in the serum should be a more reliable 
indicator of the nasal bioavailability of salmon calcition 
Optimization of formulations 
Six formulations resulting from using 3 levels of tonicity and 2 levels of 
viscosity were administered to rabbits. The area under the curve was 
calculated and analyzed by ANOVA. The results generated from the 
experimental data suggested that hypertonic and hypotonic formulations 
were significantly different from isotonic formulations at both low and high 
viscosity. The results were confirmed using Scheffe's multiple comparison 
test. Regression was carried out to define the relationship between area under 
the curve and the independent factors of tonicity and viscosity; and the 
optimum region wa~ determined by the response surface analysis. 
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A saddle point curve (figure 9) was obtained which suggests that there is no 
maximum or minimum tonicity but that a deviation from the mid point 
(isotonicity) would favor an increase in the area under the curve and 
ultimately bioavailability. Viscosity, used as a covariate and plotted along 
with tonicity and area under the curve demonstrated that there was no 
influence of viscosity on the area under the curve and subsequently 
bioavailability. This lack of increasing viscosity effect is shown in figure 9 
which indicates a AUC of 8000-10000 ng.min/ml for hypotonic formulations 
through out the viscosity range from 1 to 80 cps. There is a decrease in the 
AUC from 8000 to 2000 ng.min/ml as the tonicity increases to 300 mOsm. 
Again the surface shows a increase as the tonicity increases from 300m0sm to 
600 mOsm there is a consistent increase in AUC from 2000-6000 ng.min/ml. 
In conclusion it is feasible to enhance the absorption of sCT across the nasal 
mucosa using proper formulation variables. In spite of low plasma levels and 
bioavailability, there are clinical data which support the efficacy of intranasal 
formulations in conditions such as Paget's disease and osteoporosis. Clinical 
trials have consistently reported an excellent tolerability and acceptability of 
intranasal formulationsll. 
However further investigations are required for the evaluation of the 
toxicological effects of tonicity on the integrity of nasal mucosa, the chronic 
use of these formulations when administered intranasally may have the 
potential of damaging either the mucociliary system or the underlying 
epithelium. 
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FIGURE 9 THREE DIMENSIONAL SURFACE PLOT OF TONICITY AND 
VISCOSITY VERSUS AREA UNDER THE CURVE 
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In summary, the development and use of salmon calcitonin nasal spray holds 
a lot of promise for the future treatment and management of metabolic bone 
disorders. 
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MANUSCRIPT III 
THE INFLUENCE OF DIMYRISTOYLPHOSPHA TIDYLGL YCEROL ON 
THE NASAL ABSORPTION OF SALMON CALCITONIN 
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ABSTRACT 
The objective of this investigation was to study the effect of the phospholipid, 
dimyristoylphosphatidylglycerol (DMPG) on the intranasal absorption of 
polypeptide, salmon calcitonin (sCT). DMPG was included as an absorption 
enhancer for salmon calcitonin in a 0.03 M acetate buffer at pH 4 in a nasal 
spray formulation. The absorption of sCT was also studied as a function of 
NaCl salt concentration from 0.045-0.3 M. Serum calcitonin was determined 
using a double antibody RIA. The presence of the phospholipid demonstrated 
a significant difference in the intranasal bioavailability of salmon calcitonin. 
The results showed DMPG enhanced nasal absorption of sCT by 
approximately two fold at a salt concentration of 0.045 M. However higher salt 
concentration in the formulations demonstrated a decrease in the absorption 
enhancing effect of DMPG. The effect of DMPG on the calcium lowering effect 
of sCT was also studied. The serum calcium was quantified using arsenazo ID 
complex spectrophotometrically at 650 nm. There was no significant 
difference in the hypocalcemic activity of sCT in the presence of DMPG. In 
addition it was found that increasing viscosity of nasal formulations 
containing DMPG could not further increase the bioavailability of sCT. 
Key Words: Calcitonin, Dimyristoylphosphatidylglycerol, Absorption 
enhancer, Bioavailability, Viscosity, Salt concentration, Nasal micron spray 
pump. 
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INlRODUCTION 
The mammalian body possesses several mechanisms to restrict the entry of 
macromolecules including polypeptides and proteins. These include the 
presence of various epithelia that are poorly absorptive, the presence of 
significant levels of enzymatic activity at various locations between the point 
of entry into the systemic circulation and the target site of a peptide or 
protein, the availability of multiple enzymes to degrade peptides and proteins 
at a given location, and varying levels of immunoglobulins to neutralize 
peptides and proteins both before and after they are absorbed. The inevitable 
outcome is that the bioavailability of peptides and proteins is likely to be 
much less than that for a small molecule. 
To improve and optimize absorption of peptide and proteins, certain 
approaches and strategies have been used and these include, the use of 
penetration enhancers to alter membrane permeability, coadministration of 
inhibitors to restrain the activity of proteolytic enzymes primarily at the 
absorption site, and the use of analogs that are metabolically stable and which 
in turn may be more bioavailable. 
Among the strategies mentioned, the formulation of macromolecules with 
enhancer seems to be a realistic and viable alternative and has been a subject 
of many investigations. Penetration enhancers are compounds, generally of 
low molecular weight, that facilitate the absorption of solutes across biological 
membranes. With few exceptions and regardless of the nonparenteral route 
of administration, penetration enhancers are required for the absorption of 
peptides and proteins in pharmacologically active quantities. 
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Most of the penetration enhancers chosen for mucosal delivery have 
belonged to one of the four major classes. They are: chelators such as EDTA, 
citric acid, salicylates, N-acyl derivatives of collagen, and enamine(N-amino 
acyl derivatives of 15-diketones); surfactants such as sodium lauryl sulfate, 
polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether; bile salts such 
as sodium deoxycholate, sodium glycocholate, and sodium taurocholate; and 
fatty acids such as oleic acid and monoleinl. 
·Numerous absorption enhancers have been described for the use in the nasal 
route and their efficacy is very evident, although variable, depending on the 
peptide considered. Some of these absorption promoters include anionic and 
cationic surfactants2, bile salt-fatty acid mixed micelles3, fusidic acid 
derivatives4-6, medium chain fatty acid salts7, fatty acid derivatives of 
carnitines8, enamine derivatives of amino acids9-10, glycerine estersll, 
salicylates12-13 and carboxylic acids14 . 
Different mechanisms of action have been proposed such as alteration in the 
mucus rheology, reduction in the nasal ciliary beat frequency, enhancement 
of transcellular transport by affecting membrane lipids and proteins, 
enhancement of paracellular transport, suppression of proteolytic activity or 
enhancement of the thermodynamic activity of peptides and proteins. 
Penetration enhancers improve peptide and protein absorption by one or 
more of the several mechanisms. Bile salts have been shown to reduce the 
viscosity of the mucus layer adhering to all mucosal surfaces, thereby 
facilitating peptide and protein diffusion towards the membrane surfacelS. 
Chelators16-19 and to certain extent, polyoxyethylated nonionic surfactants20 
interfere with the ability of calcium ions to maintain the dimension of the 
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intercellular space, thereby permitting the paracellular transport of peptides 
and proteins which otherwise will be excluded from this pathway. 
Interestingly, most of the penetration enhancers are capable of increasing 
membrane fluidity either by creating disorder in the phospholipid domain in 
the membrane, as is the case of salicylates, oleic acid and monolein21-23, or by 
facilitating the leaching of proteins from the membrane, as in the case for 
surfactants and EDTA. 
The efficiency of penetration enhancers depends on several factors, including 
the nature of peptides, the physicochemical properties of the delivery system 
as related to peptide and protein release, lipophilicity of the enhancer, the 
intrinsic ability of the enhancer to perturb membrane permeability, the site of 
application of enhancer and the animal species used. 
Nature of peptide: The intrinsic ability of peptides to cross biological 
membranes is anticipated to be a complex function of their physicochemical 
properties. The bioavailability of peptide following nasal administration 
varies with their primary structure, although the precise relationship 
between absorption and physicochemical properties is as yet unknown. The 
coadministration of peptides with . 1 % sodium glycocholate elicited an 
increase in the absorption of a poorly absorbable peptide, namely leuprolide, 
However it had no effect on the absorption of metkephamid, which is 
relatively well absorbed peptide. Interestingly even in the presence of 
adjuvants, the bioavailability of leuprolide and insulin was far from 
complete24-26. 
Del_ivery systems: The selection of a delivery system for a peptide and its 
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penetration enhancer must take into account the vast difference in 
physicochemical properties that may exist between these two substances due 
to the difference in their release rates from the system. For a penetration 
enhancer to be effective, it must be released either simultaneously with the 
peptide or shortly before the peptide itself is released. This requirement is 
supported by the findings of Nishhata et al27 in that the bioavailability of 
insulin following rectal adminstration in the rat was reduced from 30.2% to 
12.8% when the release of DL-phenylalanyl ethylacetoacetate, the adjuvant, 
from the suppository was delayed from 17.5 to 30 minutes prior to the 
administration of insulin. 
Nature of enhancer: A penetration enhancer must be able to penetrate the 
membrane and at the same time, achieve a high enough comcentration to 
perturb membrane structure28. Hirai et al29 determined that somewhat 
lipophilic ester and ether type nonionic surfactants with HLB values of 10-14 
appeared to optimize the nasal absorption of insulin in the rat when 
compared with extremely hydrophilic or lipophilic derivatives. The 
coadministration of monolein and bile salts has been found to bring about a 
synergistic effect in enhancing the oral absorption of heparin in the rat 
persumably due to the facilitation of the membrane penetration of the bile 
salt by monolein30. Inspite of its attractiveness in optimizing the efficiency of 
adjuvants, the approach of using co-adjuvants that operate by different 
mechanisms has not been fully explored. 
Potency of enhancer: In a series of phenylalanylenamine type enhancers, 
which act by chealting Ca2+, the extent of hypoglycemia in rabbits following 
rectal administration of insulin was most pronounced for the most potent 
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chelators in that series31. 
Site of administration: Because the permeability characteristics of each 
mucosal site vary, the extent of absorption of a peptide differs depending on 
the site of administration32. Polyoxyethylene-9-lauryl ether and sodium 
glycocholate were far more effective in promoting the nasal absorption of 
leuprolide rather than vaginal absorption18. This was not a surprising 
finding in light of the fact that the nasal epithelium is comprised of columar 
cells whereas the vaginal epithelium is comprised of stratified squamous 
cells33. 
Animal model: The animal model that reliably mimics peptides and protein 
absorption in humans, both in the presence and absence of penetration 
enhancers, has yet to be established. Preliminary evidence suggests that, at 
least in the case of the nasal absorption of insulin, the extent of enhancement 
may be a function of the animal model chosen34-35. 
Since absorption enhancers promote peptide and protein absorption by 
perturbing membrane integrity, it is inevitable that a varying extent of 
damage would occur to these mucosal tissues which are in intimate contact 
with an enhancer. To date only few studies have been undertaken to 
determine the nature of the potentially exaggerated effects or toxicities caused 
by the various types of penetration enhancers36-38. Overall non-surfactant 
type enhancers when used on an acute basis appear to cause less severe and 
more readily reversible morphological changes than their surfactants 
counterparts. Aside from morphological changes, there is virtually no 
information on the biochemical changes that may occur locally or the 
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systemic toxicity which may result from the absorption of the penetration 
enhancers themselves and from the absorption of toxins at the mucosal 
surfaces that otherwise would be excluded from the systemic circulation. 
Membrane damaging effects have been demonstrated by protein release39, 
ciliostasis40, and histological examinations41. Such toxicity may eventually 
preclude use of these agents in clinical trials. 
Another emerging class of absorption enhancers is phospholipids. They 
occurs in cell membranes and can be classifed as acidic or zwitter ions. 
Lysophospholipids are surface active zwitter ion compounds generated 
naturally in biological membranes by action of phospholipases. They are 
active in low concentrations and are converted within the membrane to 
normal cell components42. L-a-Lysophosphatidykholine (LPC) has been 
shown to increase the permeability of rat ileum to macromolecules43 and has 
more recently been investigated as an enhancer for the intranasal absorption 
of insulin in rats44 and of human growth hormone in rats, rabbits and 
sheep45-46 although its histopathological effects on the nasal tissue have not 
been reported. The mechanisms of absorption promotion for LPC is poorly 
understood but it possesses "membrane activity" and has shown absorption 
enhancing properties45. Dimyristoylphosphatidylglycerol (DMPG) is an acidic 
phospholipid which has been shown to interact with certain polypeptides like 
glucagon, insulin, cakitonin, parathyroid, secretin, and growth hormone to 
form an amphipathic helix47. Circular Dichroism spectroscopy studies show 
that sCT forms an amphipathic helix and adopts a conformation of higher 
helical content in the presence of phospholipid DMPG48. This hydrophilic 
lipoprotein complex (DMPG-sCT) has been associated with an increase in the 
hypocakemic activity49-50 . However there have been no literature citation of 
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describing the use of DMPG as an nasal absorption enhancer for calcitionin. 
Calcitonin is a 32 amino acid amidated peptide used for over two decades to 
treat certain degenerative bone diseases and the hypercalcemia associated 
with malignancy. Before 1989, calcitonin was administered exclusively by the 
parenteral route. The bioavailability of an intravenous dose is absolute. 
However the chronic nature of the ailment and the high cost and discomfort 
associated with parenteral administration decreases patient compliance. The 
feasibility of the administration of calcitonin via the nasal route has been 
documented and the results have been encouraging51. 
Nasal spray formulations of salmon calcitonin currently are on the market in 
Europe and Japan and have been extremely well received. Similiar approvals 
are pending in the United States. These products have provided a much 
needed alternative for patients, however extremely low bioavailability of less 
than 3% of the free drug when administered nasally necessitates the use of 
absorption enhancers52. 
The objective of this investigation was to study (i) the effect of DMPG on the 
intranasal absorption of sCT in the presence of various NaCl salt 
concentrations in a range of 0.045-0.3 M (ii) the effect of DMPG on the calcium 
lowering effect of sCT (iii) whether the addition of a viscosity enhancer to 
these formulations would further increase the intranasal bioavailability of 
sCT. 
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EXPERIMENTAL 
Materials 
Salmon calcitonin (sp. activity 5384 IU /mg) was obtained from Armour 
Pharmaceuticals, Kankanee, IL. Dimyristoylphosphatidylglycerol (DMPG) was 
purchased from Avanti Lipids, Alabaster, AL. RIA Kits were procured from 
Diagnostics Systems laboratories, Webster, TX. Acetic acid and Sodium 
acetate, analytical grade were purchased from Fisher Scientific, Fair lawn, NJ. 
Anesthetics acepopromazine maleate, ketamine hydrochloride were 
purchased from Aveco Co. Inc., Fort Dodge, IA. DMA Calcium Plus 
Reagent®, DMA, Houston, TX, Methylcellulose, Methocel A15C, Dow 
Chemical Company, Midland Ml. Chlorbutanol, Sigma Chemical Company, 
St. Louis MO, Catheters and Serum separators, Baxter Health Care 
Corporation, Deerfield, IL, Heparin Sodium injection, USP, Elkins-Sinn Inc., 
Cherry Hill, NJ were purchased and used as recieved. Distilled water was used 
for all nasal formulations. 
A metered nasal spray pump was used to spray 50 µl at one time. Nasal 
micron spray pump was employed to deliver formulations of higher viscosity 
(76 cps), methylcellulose 1 % w /w. The volume delivered was 35 µl at one 
time. Both the pumps were provided by Pfeiffer GMBH, Radolfzell, Germany. 
Methods 
Preparation of formulations containing DMPG and sCT at low viscosity 
(1 cps) 
DMPG was added as a solid to a 0.03 M acetate buffer (pH 4) and the mixture 
was stirred. Calcitonin was added and it was allowed to interact at room 
temperature for 5-6 hrs. The ratio of DMPG to salmon calcitonin was 50:1, this 
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particular ratio provided a dose of sCT of 2000 IU and 1 % w /w of DMPG. The 
affinity of sCT for DMPG has been shown to be independent of temperature 
within experimental error, between 25 and 38° C and the reaction is very 
spontaneous. 
Preparation of formulation containing DMPG and sCT at high viscosity 
(76 cps) 
It has also been demonstrated53 that the addition of a viscosity enhancing 
agent increases the contact time of the dosage form with the mucosal 
membrane and may help to enhance absorption by reducing the mucociliary 
clearance of the administered drug. 
To prepare formulations containing DMPG and sCT at a higher viscosity of 76 
cps, methylcellulose was used as a viscosity enhancing agent at a 
concentration of 1 % w /w. The formulations were prepared using a hot-cold 
technique. The methykellulose was dispersed in hot water and then ice cold 
water was added and stirred for 4-5 hrs for methylcellulose to swell and 
hydrate and reach the specified viscosity. The pH was adjusted to 4. DMPG 
and calcitonin were added. The mixture was allowed to interact at room 
temperature for 5-6 hrs. 
Administration of nasal formulations to the rabbits 
It has been shown54 that by adjusting the volume and the concentration of 
intranasal drug, a significant difference in bioavailability can be obtained. The 
bioavailability of desmopressin from 2X50 µl dose was 20% greater than after 
administration of a lXlOO µl dose. Instilling the drug as a smaller volume in 
both nostrils as compared to larger volume in one nostril demonstrated 
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slower clearance from the nose. 
However the metered nasal sprays are limited 1~ fheif ·afiility to spray only 
low viscosity solutions (< 5 cps) as fine spray. The nasal micron spray pump, 
a prototype device, designed to deliver solution5 ~of higher viscosity as a fine 
spray was investigated for its use in nasal drug d~l!v-ery5~ t · 
. -ii,... -
/ _ 
A metered nasal spray pump based on the meclY~niS-m Of ball and spring with 
a flanged actuator using a spray insert of 350: s.pfaY- cfng1~twas used to spray 50 
. ,,. -
µl of low vicosity solutions (1 cps) at orie .- till\e)...,:~hd £Re?i 1fotal volume of the 
~ ... , 
dose instilled was 200 µl by spraying 2 time~~Jnto each nostril. The nasal 
micron spray pump was employed to deliver formulations of higher viscosity 
(76 cps). The volume delivered was 35 j.il" cif%rte. ti~ ~Jd a total of 210 µl 
dose was instilled by spraying 3 times info'-~atl\~strll. E nh · 
In vivo study 
Animal Model 
New Zealand white rabbits were obtairled -ff.om ;MUb'i'bol< farms (Amherst, 
MA) with a mean weight of about 3 k'g. Tne'~Sttuiiy pf-mifcdl was reviewed and 
approved by the Institutional Animal Care and Use Committee at the 
University of Rhode Island, Kingston, RI 
Experimental procedure 
The rabbits were fasted for 36 hours prior to each expe'riment with free access 
to water. The rabbit~ were anesthetized\~ifth an ·1.m-: 2tlos~ of 0.25 mg/kg of 
ketamine hydrochloride and 2.5 mg/kg ~6f· a·clipoprohla~fue maleate. Rabbits 
were kept lying on their backs on thermal rugs dtiffng ~ach experiment. A 
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catheter was placed in the rabbit's median ear artery and a 0.8-1 ml of blood 
samples was collected at -5, 10, 20, 30, 40, 50, 60, 75, 90, 120, 180, 240 and 300 
minutes after administration of the formulations. The samples were allowed 
to clot for at least 30 minutes at room temperature and then centrifuged at 
3000 rpm for 10 minutes and stored at -200 C until assayed. 
For control formulations, rabbits were anesthetized and blood was withdrawn 
at the same intervals as mentioned above and serum analyzed. This was 
called control group as no calcitonin was administered and was used to 
measure any interference from the trauma on administration of anesthesia 
on the inherent calcitonin level. The values obtained were subtracted from 
the levels obtained after administration of calcitonin formulations . 
Study Design 
The various formulations of calcitonin were administered as spray to the 
rabbits as per a randomized cross-over design. A wash out period of at least 
one week was allowed between treatments. 
Analytical methods 
Serum calcitonin 
All serum samples were assayed with a commercial RIA kit developed by 
Diagnostics Systems Labortories (Webster, TX). Guinea pig anti-sCT antibodies 
were used as primary antibodies and have demonstrated less than 2% w /w 
cross reactivity. The sigmoidal standard curve of B/Bo versus [sCT], typical of 
competitive binding assays was linearized using a log transformation of sCT. 
The best fit line was determined using a non weighted least square regression 
analysis. The radioimmunoassay quantitation range was 100-5000 pg/ml. The 
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coefficent of determination (r2) in this range for the B/Bo versus log [sCT] 
plots was greater than 0.993 for all assays performed in duplicate. 
Serum calcium levels 
Serum calcium levels were determined using a DMA Calcium Plus 
Procedure® utilizing arsenazo III to bind the calcium at an acid pH and 
form a bluish purple complex. Color intensity was measured 
spectrophotometrically at 650 nm. The range of the linearity was determined 
to be between 5-25 mg/ dl. The coefficient of determination (r2) in this range 
for the absorbance versus concentration (mg/ dL) was 0.999 for all the assays 
performed in duplicate during the course of study. 
Data Analysis 
The nasal bioavailability of calcitonin was calculated relative to the serum 
cakitonin levels after injecting calcitonin intravenously. Cmax values are the 
peak serum calcitonin concentrations observed at time Tmax after 
adminstration of calcitonin. 
%Absolute Bioavailability = AUCin-AUCcontrol X Doseiv X 100 
AUCiv-AUCcontrol Dosein 
where AUCin, AUCiv and AUCcontrol refer to the area under the curve 
calculated by the linear trapezoidal rule. AUCin refers to area under the curve 
calculated after the intranasal administration of calcitonin formulations. 
A U Civ refer s to area under the curve calculated after the intravenous 
administration of calcitonin formulations. AUCcontrol refers to area under the 
curve calculated without administration of cakitonin. 
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The hypocalcemic effect was measured in terms of percent maximal decrease 
(%maxd); which is defined as the highest percentage of reduction in calcium 
levels as compared to the basal values. The total decrease in serum calcium 
level (D%) was calculated by a modified method, from Hirai et al, 1981. 
D% = AUCcontrol-AUCin X lOO AUCcontrol 
where AUCin, AUCcontrol and AUCiv refer to the area under the curve 
calculated by the linear trapezoidal rule after the intranasal administration of 
calcitonin formulations. The time at which this reduction takes place is Tmax. 
Statistical analysis was performed using ANOVA by Statistical Analytical 
Software (SAS). Formulation effects were compared with the controls using 
Dunnett's test. Multiple comparison among the treatment effects were 
determined using Scheffe's multiple comparison test. Differences among the 
treatment were assumed to be significant for values of p < 0.05. 
Selection of best formulations 
The primary aim of this investigation was to study the effect of DMPG on the 
intranasal bioavailability of sCT. The influence of DMPG was investigated at 
the three levels of salt concentration of 0.045 M, 0.15 Mand 0.3 M. In order to 
optimize the effect of these salt concentrations and the concentration of 
DMPG on area under the curve, response surface analysis was applied. The 
SAS/RSREG was used to fit the parameters of the complete quadratic reponse 
surface obtained at the three levels of salt concentration incorporated in the 
formulations and analyze the fitted surface to determine the level of the salt 
concentration needed for the optimum form ulations. The predicted optimal 
value can be found from the estimated surface, which usually shows a 
mif1:ima, maxima or saddle point, Since the independent variable should be 
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at three or more levels, salt concentration was designated as independent 
variable with area under the curve as a response surface and the 
concentration of DMPG was used as a covariate investigated at two levels.56 
RES UL TS AND DISCUSSION 
Currently, two classes of nasally delivered therapeutic compounds are on the 
market. The first and largest class encompasses low molecular weight drugs 
designed to treat local inflammation of the nasal mucosa and sinuses. This 
class includes topical steroids, cromolyn sodium, and most over the counter 
nasal products. These compounds are generally hydrophobic in their un-
ionized form, and readily partition into the mucosal membrane. The second 
class includes those drugs intended for systemic delivery after intranasal 
administration. Despite the attractiveness of the nasal cavity for systemic 
administration, the second class includes only a few compounds: vasopressin, 
oxytocin, LH-RH analogs, calcitonin, and vitamin B-12. Except for vitamin B-
12, the compounds are all peptides and show very low bioavailability. 
Although the bioavailability of these peptides is low, therapeutic activity may 
often be sufficient because of the high biological potency of these compounds. 
This study was designed to evaluate the phospholipid, DMPG, as an 
absorption enhancer and to determine its ability to enhance the 
bioavailability of salmon calcitonin. Phospholipids may be directly involved 
in the binding of many drugs and hormones to specific cell-surface receptors 
sites47-48, There is evidence that binding to lipid is required for the activity of 
peptides including enkephalin57 and thyrotropinSB. Calcitonin is a 
membrane active peptide and its interaction with the lipid may be related to 
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its biological activity. Circular Dichroism spectroscopy studies show that 
salmon calcitonin (sCT) forms an amphipathic helix and adopts a 
conformation of higher helical content in the presence of the phospholipid, 
Dimyristoylphosphatidylglycerol (DMPG). This hydrophilic lipoprotein 
complex has been associated with an increase in the hypocalcemic 
activity48-50. 
Pharmacokinetic studies 
Since salts are often used in nasal formulations to adjust ionic strength, 
tonicity etc, it was decided to investigate the effect of salt concentration on the 
absorption of sCT with or /without DMPG. Table I summarizes the Tmax, 
Cmax, AUC and Bioavailability for the formulations investigated. In order to 
determine the absolute bioavailability of intranasal sCT formulations, the 
AUC for the control formulation and i.v solution was also determined and 
was calculated to be 401±75.3 and 1102.1±19.8 ng.min/ml. 
Low viscosity formulations 
Effect of 0.045 M Na Cl 
The influence of DMPG on the absorption of sCT in a formulation containing 
0.045 M N aCl at a viscosity of 1 cps is shown in figure 1. The Cmax obtained 
for the formulation containing only sCT was 26±7.6 ng/ml at 38 minutes 
whereas the Cmax elicited by the formulation containing only DMPG and sCT 
increased to 82±30 ng/m l at 90 minutes. The AUC elicited by sCT formulation 
at 0.045 M NaCl w as 3171±258 ng.min/ml and an absolute bioavailability of 
0.71 whereas the AUC elicited by formulation incorporating DMPG and sCT at 
0.045 M NaCl was 6017±706 ng.min/ml with an absolute bioavailability of 1.4. 
The presence of DMPG and sCT in the formulation demonstrated a two fold 
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Figure 1 THE INFLUENCE OF A SALT CONCENTRATION OF 
0.045 MAND DMPG ON THE INTRANASAL ABSORPTION 
OF SALMON CALCITONIN 
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TABLE I PHARMACOKINETIC PARAMETERS OF LOW VISCOSITY SALMON CALCITONIN 
FORMULATIONS AFTERINTRANASAL ADMINISTRATION IN NEW 
ZEALAND RABBITS (N = 5) 
VARIABLE Tmax (min) ~ Cmax(ng/ml) AUC(ng.min/ml) 
CONTROL 401±75.3 
J.V (5 I.U.) 14 25 ± 2.9 1102.l ± 19.8a 
INTRANASAL 
§.ct: 
DOSE 2000 I.U. 
o.045 M 38 26 ± 7.6 3171±258b 
O.lSM 40 10 ±4.2 714.2 ± 15.7C 
0.3M 90 42±19.6 3508±1280 
I 
INTRANASAL 
DMfS:Z-11CT 
DOSE 2000 I.U. 
0.045M 90 82±30 6017± 706b 
0.15M 10 22 ±30 1521±275c 
O.JM 63 28±7.5 3692± 1369 
a significantly different from control at p<0.05 
b significantly different in AUC for DMPG formulations at 0.045 M NaCl at p<0.05 
c significantly different in AUC for DMPG formulations at 0.15 M NaCl at p<0.05 
%Bioavailabili~ 
100 
0.71 
0.16 
0.80 
1.4 
0.34 
0.84 
-..._ 
increase in the absorption of sCT as compared to formulation containing only 
sCT at a NaCl concentration of 0.045 Mand a viscosity of 1 cps. 
Effect of 0.15 M NaO 
The influence of DMPG on the absorption of sCT from formulations 
prepared with 0.15 M NaCl at a viscosity of 1 cps is shown in figure 2. The 
Cmax was found to be 10± 4.2 ng/ml at 40 minutes for the formulations 
containing only sCT whereas the Cmax increased to 22 ng/ml at 10 minutes 
for the formulations incorporating DMPG and sCT. The AUC elicited was 
714.2 ng.min/ml and an absolute bioavailability of 0.16 for the sCT 
formulation as compared to an AUC of 15~1 ng.min/ml and an absolute 
bioavailability of 0.34 for the formulations containing DMPG and sCT. These 
results demonstrated that even at a NaCl salt concentration of 0.15 M and a 
viscosity of 1 cps, the bioavailability elicited by the presence of DMPG in sCT 
formulations increased two fold compared to sCT formulations without 
DMPG. However the bioavailability elicited by sCT with a 0.045 M NaCl salt 
concentration and a viscosity of 1 cps was higher as compared to formulations 
containing sCT at a 0.15 M NaCl salt concentration and a viscosity of 1 cps 
(1.4% versus 0.34%). 
Effect of 0.3 M Na Cl 
The influence of increasing the NaCl salt concentration to 0.3 M with a 
viscosity of 1 cps in the absence or presence of DMPG on the bioavailability of 
sCT is shown in figure 3. The Cm ax was 42±19.6 ng/ml at 90 minutes for the 
sCT formulations. The Cmax was reduced to 28±7.5 ng/ml at 63 minutes in 
the presence of DMPG in the sCT formulations. The AUC for the sCT 
administration was 3508±1280 ng.min/ml with an absolute bioavailability of 
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Figure 2 THE INFLUENCE OF A SALT CONCENTRATION OF 
0.15 M AND DMPG ON THE INTRANASAL ABSORPTION 
OF SALMON CALCITONIN 
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Figure 3 THE INFLUENCE OF A SALT CONCENTRATION OF 
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0.80 as compared to an AUC of 3692±1369 ng.min/ ml and an absolute 
bioavailability of 0.84 in the presence of DMPG in sCT formulations. 
Therefore in the presence of higher salt concentration of 0.3 M NaCl, the 
absorption of sCT was not affected by the presence of DMPG, in fact it was 
approximately the same magnitude as seen w ithout addition of DMPG. This 
indicated that DMPG did not have any absorption enhancing effect on sCT 
absorption at 0.3 M. Therefore maximum bioavailability elicited by DMPG 
and the sCT formulations was obtained at the lowest concentration of NaCL 
Pharmacodynamic effects 
It has been suggested that the presence of DMPG in an sCT formulation 
enhances the helical activity of sCT and may be related to the increase in the 
hypocalcemic activity48-SO. Thus the parameters of hypocalcemic activity 
were determined for formulations containing only sCT and those containing 
DMPG along with sCT. The results are summarized in Table II as Tmax (min), 
%maxd (percent maximal decrease), AUC (mg.min/dL) and D% (total 
hypocalcemic activity). 
Low viscosity formulations 
Effect of 0.045 M Na Cl 
The influence of DMPG on the calcium level after intranasal administration 
of sCT in the presence of 0.045 M NaCl at a viscosity of 1 cps is shown in 
figure 4. The maximal decrease, %maxd was 28.12% at 180 minutes for sCT 
formulations as compared to %maxd of 34.58% at 120 minutes for 
formulations incorporating DMPG and sCT. The AUC was 3308±42.45 
mg.min/ dL and a total lowering of calcium, D% of 18% for sCT formulations 
as compared to a AUC of 3209.55±21.66 mg.min/ dL with D% of 19% in the 
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TABLE II PHARMACODYNAMIC PARAMETERS OF LOW VISCOSITY SALMON CALCITONIN 
FORMULATIONS AFTER INTRANASAL ADMINISTRATION INTO NEW ZEALAND RABBITS 
(N =5); DOSE = 2000 I. U. 
• 
VARIABLE Im~~(minl MaxdJ.%1 A:UC (rng.min/dLl .%..D. 
CONTROL 4045.40 ± 255.17 
.. 
I.V (5 l.U.) 30 28 2732 ± 271.39a 32 
sCT 
0. 045M 180 28.12 3308.0 ± 42.45 18 
0.15M 240 12.96 3724.12±120.99b 7.9 
0.3M 180 28.83 3267.74 ± 31.31 19 
QMPG-sCT 
0.045M 120 34.58 3209.55 ± 21.66 19 
0.15M so 38.89 2884.70 ± 53,24b 20 
0.3M 90 38.49 3208 ± 102.49 20 
a= significantly different from control at p> 0.05 
b =significantly different in calcium levels at p> 0.05 
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FIGURE 4 THE INFLUENCE OF A SALT CONCENTRATION 
OF 0.045 M AND DMPG ON THE CALCIUM LEVEL AFTER 
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sCT formulations incorporating DMPG. Thus for formulations containing 
0.045 M NaCl salt and a viscosity of 1 cps, the maximal decrease in calcium 
elicited by the presence of DMPG and sCT was higher (34.15% versus 28.12%), 
but D%, which is the overall measure of the hypocalcernic activity of sCT was 
similiar (18% versus 19%) to sCT formulations. Thus there was no significant 
difference in the total hypocalcemic activity elicited by formulations with or 
without the enhancer at p <0.5. 
Effect of 0.15 M NaCl 
The influence of DMPG on the calcium level after intranasal administration 
of sCT in the presence of 0.15 M NaCl at a viscosity of 1 cps is shown in figur~ 
5. The %maxd was 12.96% at 240 minutes and 38.89% at 50 minutes in the 
absence and presence of DMPG in the sCT formulations respectively. The 
AUC was 3724.12±120.99 mg.min/dL with a total lowering of calcium, D% of 
7.9% for sCT formulations as compared to the AUC of 2884.70±53.24 
mg.min/ dL with a D% of 20% in the presence of DMPG in sCT formulations. 
The comparison of AUC and a D% for these two formulations demonstrated 
that there was a significant difference on the total lowering of calcium level 
in the presence of DMPG in sCT formulations at a salt concentration of 0.15 M 
and a viscosity of 1 cps as compared to sCT formulations (20% vs 7.9%) at 
p <0.05. 
Effect of 0.3M Nao 
The influence of DMPG on the calcium level after intranasal administration 
of formulations containing sCT in the presence of 0.3 M NaCl at a viscosity of 
1 cps is shown in figure 6. The maximal decrease was 28.83% at 180 minutes 
for formulations containing only sCT as compared to 38.49% at 90 minutes for 
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FIGURE 5 THE INFLUENCE OF A SALT CONCENTRATION 
OF 0.15 M AND DMPG ON THE CALCIUM LEVEL AFTER 
INTRANASAL ADMINISTRATION OF SALMON CALCITONIN 
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FIGURE 6 THE INFLUENCE OF A SALT CONCENTRATION 
OF 0.3 M AND DMPG ON THE CALCIUM LEVEL AFTER 
INTRANASAL ADMINISTRATION OF SALMON CALCITONIN 
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formulations incorporating DMPG and sCT. The AUC was 3267.74±31.31 
mg.min/ dL and a total lowering of calcium, D% of 19% for sCT formulations 
as compared to AUC of 3208±102.49 mg.min/ dL with a D% of 20% for 
formulations containing DMPG and sCT. This indicated that the total 
lowering in calcium was comparable, in the absence and presence of DMPG at 
a salt concentration of 0.3 M (19% versus 20%). Therefore the calcium 
lowering effects of sCT were demonstrated to be not affected by presence of 
DMPG when the salt concentration was 0.3 M. 
The hypocalcemic activity was comparable for formulations containing only 
sCT and for formulations incorporating DMPG with sCT at a NaCl salt 
concentration of 0.045 M and 0.3 M at the low viscosity of 1 cps. However at a 
NaCl salt concentration of 0.15 M with a viscosity of 1 cps, the formulations 
containing DMPG with sCT showed a significant difference in the calcium 
lowering effect of salmon calcitonin. However in all the three salt 
concentrations the total lowering of calcium ranged from 7.9% to 20%. The 
Tmax calculated as a pharmacodynamic parameter for the maximum 
lowering of calcium ranged from 50 to 240 minutes indicating the 
pharmacodynamic acitivity of salmon calcitonin in lowering of calcium is 
sustained and does not correlate with the presence of calcitonin in the serum. 
Influence of viscosity 
It was hypothesized that higher viscosity formulations may act in synergism 
with the absorption enhancing effect of DMPG at a NaCl salt concentration of 
0.045-0.3 M. The pharmacokinetic parameters obtained after administering 
the absorption enhancer, DMPG in sCT formulations at the higher viscosity 
of 76 cps were compared to the low viscosity formulations of 1 cps, with and 
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without the DMPG. The study was designed to evaluate the use of high 
viscosity (- 75 cps) formulations obtained by using 1% w /w methykellulose 
delivered as a fine spray with a prototype device, the nasal micron spray 
pump, to facilitate the uniform distribution of spray in the nasal cavity55. 
It has been demonstrated53 that the addition of methykellulose produced a 
more sustained and slower absorption as indicated by the difference in time to 
reach maximum plasma concentrations. However the AUC data indicated a 
similiar bioavailability for the two formulations . It is thought that the 
addition of a viscosity enhancing agent such as methykellulose increases the 
contact time of the dosage form to the mucosal membrane and may help in 
enhancing the absorption by reducing the mucociliary clearance of the 
administered formulation and also changing the pattern of deposition and 
clearance59 An increase in viscosity increases the particle size in a spray 
formulation. It also leads to a more localized deposition on the anterior part 
of the nose and thus facilitates slower clearance60. 
On the other hand, with regard to mucociliary clearance, results are difficult 
to interpret. According to some authors, an increase in viscosity results in a 
decrease in the clearance rate61. Viscosity also influences the rate of diffusion 
of the active ingredient resulting in delayed release without any 
improvements in bioavailability62. 
The influence of viscosity on formulations containing DMPG as compared to 
formulations without DMPG at a NaCl concentration of 0.045-0.3 M are 
shown in figure 7-9. The pharmacokinetic parameters of these formulations 
are summarized in Table III. 
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TABLE III PHARMACOKINETIC PARAMETERS OF HIGH VISCOSITY SALMON CALCITONIN 
FORMULATIONS AFTERINTRANASAL ADMINISTRATION IN NEW 
ZEALAND RABBITS (N = 5) 
VARIABLE Tmax (min) ~ Cmax(ng/ml) AUC(ng.min/ml) 
CONT ROL 401±75.3 
I.V (S l.U.) 14 25 ± 2.9 1102.1 ± 19.8a 
INTRANASAL 
sCT 
DOSE 2000 I.U. 
0.045 M 120 23 ± 2.4 3579± 103 
0.15M 58 12 ±9.7 604.64± 97.74b 
0.3M 90 32±19.6 3589± 25c 
' 
INTRANASAL 
QMfG-~CT 
DOSE 2000 I.U. 
0.045 M 90 54±24 4203 ±384.1 
O.lSM 10 13 ± 7 1244 ± 275b 
0.3M 63 8±7.5 2134± 1369C 
a significantly different from control at p<0.05 
b significantly different in AUC for DMPG formulations at 0.15 M NaCl at p<0.05 
c significantly different in AUC for DMPG formulations at 0.3M NaCl at p<0.05 
%Bioavailability 
100 
0.71 
0.14 
0.72 
0.96 
0.28 
0.56 
( 
High Viscosity formulation 
Effect of 0.045 M NaO 
The influence of DMPG on the absorption of sCT in formulations containing 
0.045 M NaCl at a viscosity of 76 cps is shown in figure 7. The Cmax was 23 
ng/ml at 120 minutes for the sCT formulations as compared to the Cmax of 
54±24 ng/ml at 55 minutes elicited by the presence of DMPG in sCT 
formulations. The AUC was 3579±103.0 ng.min/ml in the absence of DMPG 
and 4203±706 ng.min/ml in the presence of DMPG with an absolute 
bioavailability of 0.81 and 0.96 respectively. The presence of DMPG at a high 
viscosity of 76 cps did not make a significant difference in the bioavailability 
of sCT at a NaCl concentration of 0.045 M (0.96 vs 0.81). However DMPG at a 
low viscosity of 1 cps elicited a two fold increase in the bioavailability (1.4 vs 
0.71). This can be explained by the fact that increased viscosity reduces the 
diffusion of the drug from the formulation to the site of absorption. Thus the 
tmax is increased to 60 and 120 minutes for the two high viscosity 
formulations as compared to the 38 minutes for the low viscosity 
formulations without much improvement in bioavailabity. 
Effect of 0.15 M NaO 
The effect of the formulation containing DMPG and sCT at a NaCl 
concentration of 0.15 Mat 76 cps is shown in figure 8. The Cmax obtained for 
formulations containing only sCT was 12±9.7 ng/ml at 58 minutes as 
compared to the Cmax for formulations containing DMPG and sCT of 13±7 
ng/ml at 90 minutes . The AUC was 604.64 ng.min/ml and an absolute 
bioavailability of 0.14 for sCT formulation whereas an AUC of 1244.914±275.65 
ng.min/ml and a bioavailability of 0.28 was obtained for the formulations 
containing DMPG and sCT. At NaCl salt concentration of 0.15 M, there was a 
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two fold increase (0.28 vs 0.14) in the bioavailability of sCT in the presence of 
DMPG at a high viscosity of 76 cps . These results were very similiar to those 
obtained at low viscosity formulations of 1 cps at a salt concentration of 0.15 
M . 
Effect of 0.3 M NaO 
The effect of the formulation containing DMPG and sCT at a NaCl 
concentration of 0.3 M and 76 cps is shown in figure 9. The Cmax was 32±19.6 
ng/ml at 90 minutes for the salmon calcitonin formulations. The Cmax was 
8±7.5 ng/ml at 63 minutes for DMPG and sCT formulations . The absolute 
bioavailability of 0.72 was obtained for sCT formulations in the presence of 0.3 
M salt as compared to a bioavailability of 0.56 for formulations containing 
DMPG and sCT in the presence of 0.3 M as shown inTable III. This 
demonstrated that in the presence of higher salt concentration of 0.3 M NaCl 
the DMPG did not elicit an absorption enhancing effect. These results 
correlated with results obtained for low viscosity formulations at 0.3 M NaCl 
salt concentration. 
Pharmacodynamic effects 
High viscosity formulations 
The parameters for the hypocalcemic activity of the high viscosity 
formulations with and without DMPG are summarized in Table IV as 
Tmax(min), %maxd (maximal percent decrease), AUC (mg.min/ dL) and D% 
(total hypocalcemic activity). A review of the pharmacodynamic effect of sCT 
of lowering of calcium is illustrated in figures 10-12. 
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Figure 9 THE INFLUENCE OF A SALT CONCENTRATION OF 
0.3 M AND DMPG ON THE INTRANASAL ADSORPTION 
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TABLE IV PHARMACODYNAMIC PARAMETERS OF HIGH VISCOSITY SALMON CALCITONIN 
FORMULATIONS AFTER INTRANASAL ADMINISTRATION INTO NEW ZEALAND 
RABBITS (N =5); DOSE = 2000 I. U. 
YARIABLE Tmax(min) "loMaxd AUC (mg.min/dl) %D 
CONTROL 4045.40 ± 255.17 
I.V (5 I.U.) 30 .. 28 2732 ± 271.39a 32 
INTRANASAL 
&I 
DOSE 2000 I.U. 
0.045M 120 34.58 3154.47 22 
0.15M 240 28.81 3242.83b 19 
0.3M 90 23.52 ' 3696.28 . 9 
INTRANASAL 
DM~Q&~CT 
DOSE 2000 I.U. 
0.045M 90 28.36 3331 17 
0.15M 180 27.09 3161.67 21 
0.3M 75 29.01 3510.80 13 
a significantly different from control at p<0.05 
b significantly different in AUC for DMPG formulations at 0.15 Mat p<0.5 
( 
\ 
Effect of 0.045 M NaO 
The influence of DMPG on the calcium level after intranasal administration 
of sCT in the presence of 0.045 M NaCl and at a viscosity of 76 cps is shown in 
figure 10. The maximal decrease was 34.58% at 300 minutes and 28.36% at 90 
minutes in the absence and presence of DMPG respectively. A total lowering 
of calcium of 22% for formulations containing sCT whereas a D% of 17% for 
formulations incorporating DMPG in sCT was obtained. There was no 
significant difference on the calcium level in the absence or presence of 
DMPG at 0.045M NaCl at a viscosity of 76 cps. 
Effect of 0.15 M NaO 
The influence of DMPG on the calcium level after intranasal administration 
of sCT in the presence of 0.15 M NaCl and at a viscosity of 76 cps is shown in 
figure 11. The %maxd was 28.81 % at 240 minutes and 27.09% at 180 minutes 
in the absence and presence of DMPG respectively. The AUC was 3242.83 
mg.min/ dL with a D% of 19% for formulations containing sCT and 3161.679 
mg.min/dL with D% of 21% for formulations containing DMPG and sCT. The 
comparison of AUC and a· D% of these two formulations demonstrated that 
there was no significant difference in the calcium level by high viscosity 
formulations at a salt concentration of 0.15 M containing enhancer or without 
enhancer. These results were different from those obtained at a low viscosity 
of 1 cps where there was a significant difference in the overall hypocalcemic 
activity of formulations with and without enhancer. The reason for this 
difference is not known. 
Effect of 0.3 M NaO 
The influence of DMPG on the calcium level after intranasal administration 
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of sCT in the presence of 0.3 M NaCl and a viscosity of 76 cps is shown in 
figure 12. The %maxd was 23.52% at 90 minutes and 29.01 % at 75 minutes in 
the absence and presence of DMPG respectively. The AUC was 3696.28 
mg.min/ dL with a D% of 9% was calculated for formulations containing only 
sCT as compared to the AUC of 3510.801 mg.min/ dL with a D% of 13% 
obtained by formulations containing containing DMPG and sCT. Again there 
was no significant difference in the total calcium lowering effect of sCT in the 
absence and presence of DMPG (9% vs 13% ). 
The similarity in the extent of the hypocalcemic effect observed for the 
different formulations of sCT especially those which demonstrated significant 
differences in absorption of sCT may be attributed to the acute homeostatic 
mechanism between calcitonin and parathyroid hormone. The parathyroid 
hormone counteracts the effects of calcitonin once a critical level of 
hypocalcemia is attained. Thus the extent of the hypocalcemic effect is 
controlled by the hormonal balance. The acute control of blood calcium is 
accomplished by the feedback action of calcitonin and parathyroid 
hormone63. This complex regulation of blood calcium concentration makes it 
difficult to evaluate the efficacy of sCT delivery systems by observation of the 
hypocalcemic effect. Additionally the short half life of sCT makes it more 
difficult to correlate serum sCT and its biological effects64. 
Selection of the best formulations 
Response surface methodology was used as a optimization technique to select 
the levels of the variables that could best describe the most desirable 
attributes of the formulation. The response surface analysis plot 
demonstrated that a maxima was obtained, which suggests that there is a 
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Figure 13 THREE DIMENSIONAL SURFACE PLOT SHOWING 
MAXIMA FOR DMPG AND SALT CONCENTRATION WITH 
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optimum salt concentration to deliver DMPG. The three dimensional plot 
included concentration of NaCl on X-axis, concentration of DMPG on Y-axis 
and AUC on Z-axis. Figure 13 indicates an AUC of 25000-30000 ng.min/ml for 
0.045M formulations with DMPG at a concentration of 2% and a AUC of 0-
50000 ng.min/ml for formulations with a NaCl of concentration > 0.25M and 
a DMPG of 0-0.5% w /w concentration. Thus the analysis suggests that the 
most effective formulation should contain DMPG at a salt concentration of 
0.045M to provide the best absorption enhancing effect of DMPG on salmon 
ca lei tonin. 
To overcome the low bioavailability of higher molecular weight polypeptides 
in intranasal delivery, it becomes necessary to include an absorption 
enhancer. However the choice of absorption enhancer is very important as it 
should be able to increase the uptake of the peptide, at the same time it 
should be safe, nontoxic in long term use and should not alter the physiology, 
histology of nasal cavity. This study not only investigated the role of DMPG 
in enhancing the absorption but also the effect of other formulation factors 
such as viscosity and salt concentration on the efficacy of this enhancer. Very 
little work has been done on phospholipids as absorption enhancers, 
especially acidic absorption enhancers. It is extremely important to study their 
effects after chronic use on ciliary beat freqency, histology and physiological 
functions before they can be approved as an excipient in the formulations 
meant for nasal delivery. 
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CONCLUSIONS 
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1. A study of delivery devices and components which used the Malvern 
laser sizer to determine the qualitative and quantitative spray profile 
indicated that the currently available metered nasal devices were capable 
of dispensing low viscosity solutions as a fine spray and maintaining a 
Gaussian distribution. The devices also demonstrated an excellent total 
dose delivery and reproducibility for all types of solutions. 
2. The nasal micron spray pump, a prototype device, that was developed 
for pulmonary drug delivery is very versatile and can be extremely 
valuable in nasal drug delivery. It is capable of generating a 
3. 
narrower droplet size distribution and a fine spray for viscous 
solutions which cannot be achieved with currently available spray 
pumps. 
Among the formulation variables investigated, tonicity elicited a 
significant difference in achieving a higher concentration of salmon 
calcitonin in the serum and enhancing the bioavailability of salmon 
ca lei tonin. 
4. Viscosity studied at the two levels indicated that although the droplet 
spray distribution was significantly affected, no significant improvement 
in the bioavailability of salmon calcitonin was found for solutions 
differing in viscosity. 
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5. The use of dimyristoylphosphatidylglycerol, an acidic phospholipid, a 
novel permeation enhancer demonstrated an increase in the 
bioavailability of salmon calcitonin. 
6. The absorption enhancing activity of dimyristoylphosphatidylglycerol 
when studied as a function of salt concentration indicated that a low salt 
concentration was required for the optimal activity. 
7. The pharmacodynamic effect of salmon calcitonin of lowering of 
calcium indicated that although it was a useful parameter for indirectly 
measuring the efficacy of salmon calcitonin formulations, it did not 
correlate directly with the plasma concentration of the drug and was very 
difficult to interpret the results. This inconsistency was attributed to the 
fact that the hypocalcemic response is controlled by the parathyroid gland 
which correctively responds to cakitonin plasma concentration. 
8. The low bioavailability of higher molecular weight polypeptides such as 
salmon calcitonin can be enhanced by a optimization of both 
formulation parameters and nasal administration device variables. 
This investigation emphasized a need to study both formulation and 
devices variables to overcome low bioavailability. This approach is of 
tremendous value to the formulation scientist by increasing the 
probability of optimizing drug delivery and accelerating product 
development. 
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APPENDIX A 
TECHNIQUES USED FOR ANALYSIS 
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QUANTITATIVE DETERMINA ITION OF SALMON CALCITONIN IN 
SERUM 
Double Antibody Radioimmunoassay 
Principle 
Double antibody radioimmunoassay is a sequential competitve 
radioimmunoassay. The sample is first preincubated with anti- calcitonin 
serum. 125_1 -labeled calcitonin then competes with the calcitonin in the 
serum samples for antibody sites. After incubation for a fixed time, separation 
of bound from free is achieved by the PEG- acclerated double antibody 
method. The antibody-bound fraction is precipitated by centrifugation under 
refrigerated conditions. The precipitated pellets are counted by a gamma 
counter. 
Reagents provided (Diagnostics Systems Limited, Webster, TX) 
1. Calcitonin Antiserum contains guinea pig as primary antibodies. 
2. 125 I- Calcitonin 
3. 125 I- Calcitonin calibrators. 
Six vials labeled A through E with 0 to 50 ng/ml concentration of 
salmon calcitonin. 
4. Precipitating reagent 
One vial of precipitating reagent consisting of guinea pig-antigoat 
gamma globulin in polyethlene glycol. 
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5. Calcitonin controls 
Two vials labeled calcitonin controls I and II containing calcitonin in a 
protein based matrix containing 2 mg/ ml and 10 ng/ml as low and 
high control levels of salmon calcitonin. 
All the samples except precipitating reagent were lyophilized. They were 
stored in refrigerator and were reconstituted with distilled water for 30 
minutes before the use. 
Procedure 
Serum samples were incubated with calcitonin antiserum for 6 hrs at 2-80C. 
After the first incubation, radiolabeled calcitonin was added and samples 
reincubated for 24 hrs at 2-80C. Separation was achieved by the addition of 
precipitating reagent and was followed by a third incubation for 1 hr. THe 
samples were centrifuged for 30 minutes aat 3000 rpm at 2oC. The 
supernatant was drained off, the rim of tubes wiped to eliminate radioactive 
contamination and precipitated pellets were counted in a gamma counter for 
1 minute in terms of cpm (counts per minute) and analysis of each sample 
was performed in duplicate. 
Calculations 
To be able to calculate the concentration of calcitonin on serum samples, the 
first step was to calculate the total count, non-specific binding, maximum 
binding and %B/Bo. 
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The cpm of 125 Iodinated Calcitonin was counted and termed as total counts. 
The nonspecific binding (NSB) was determined by using deionized water 
instead of serum samples and was subtracted from the readingt in cpm 
obtained for all serum samples, 
Net Count= average cpm - average NSB cpm 
Maximum binding was provided by zero ng/ml of calcitonin standard. The 
counts obtained by Ong/ml and subtracted by non-specific binding was taken 
to be 100% and was called maximum binding. 
Percent bound (B/Bo) =Net count X 100 
Net maximum binding 
The sigmoidal standard curve of B/Bo vs log[sCT], typical of competitive 
binding assays was linearized using the log transformation. Using th.e linear 
log graph paper, percent bound was plotted on the vertical axis against 
concentration on the horizontal axis for each of the nonzero calibrators. The 
best fit was determined using a non weighted least square regression analysis. 
Results 
The radioirnrnunoassay quantitation range was 100 pg/ml- 5000 pg/ml. The 
square of the coefficient of determination on this range for the B/Bo versus 
log[sCT] plots was greater than 0.993 for all assays performed in duplicate. 
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QUANTITATIVE DETERMINATION OF CALCIUM IN SERUM 
CALCIUM PLUS® PROCEDURE 
Principle 
The calcium plus® procedure developed by DMA, Houston, TX., utilizes a 
dye, arsenazo III which binds to calcium at an acid pH. A bluish - purple 
complex is formed. The intensity of the color formed is measured by an 
increase in absorbance of the reaction mixture at 650 nm. 
Reagents Provided 
Calcium plus® reagent 
Control sera of concentration of calcium 10 mg/ dL 
Composition of Calcium Plus Reagent 
Arsenzo ill (0.136 mmol/L) 
Buffer 
Surfactant 
Sodium azide 
Manual Procedure 
1. Add 2 ml of calcium plus reagent into labeled test tubes. 
2. Add 0.025 ml of each control and samples to their respective test tubes. 
3. Mix well 
4. Use 0.025 ml deionized water for reagent blank instead of sample or control. 
5. Incubate for 2 minutes at the reaction temperature. 
166 
( 
6. Set the wavelength of the instrument at 650 nm. Zero with the reagent 
blank. 
7. Read and record absorbance of the samples and controls. 
Calculations 
Absorbance of unknown X Concentration of standard = Calcium (mg/dL) 
Absorbance of standard 
RESULTS 
Serum calcium was quantified by uv spectroscopy and the range of the 
linearity was determined to be between 5 mg/ dL - 25 mg/ dL. The square of the 
coefficient of determination in this range for the absorbance (AUFS) versus 
concentration (mg/ dL) was 0.999 for all the assays performed in duplicate 
during the course of study. 
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APPENDIX B 
STATISTICAL DATA SUPPORTING MANUSCRIPT I 
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STATISTICAL ANALYSIS OF MALVERN DATA 
FORMULATION VARIABLE - VISCOSITY 
Analysis of Variance Procedure 
Dependent Variable: MSO 
Sum of Mean 
Source OF Squares Square F Value Pr> F 
Model 2 6204.0566000 3102.0283000 126.56 0.0001 
Error 6 147.0588000 24.5098000 
Corrected Total 8 6351.1154000 
R-Square C.V. Root MSE M50Mean 
0.976845 7.138084 4.9507373 69.356667 
Dependent Variable: M90 
Sum of Mean 
Source OF Squares Square F Value Pr::> F 
Model 2 90381.751489 45190.875744 229.02 0.0001 
Error 6 1183.945667 197.324278 
Corrected Total 8 91565.697156 
R-Square C.V. RootMSE M90 Mean 
0.987070 8.366806 14.047216 167.89222 
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STATISTICAL ANALYSIS OF i\IALVERN DATA 
FORMULATION VARIAllLE - TONICITY 
Analysis of Variance Procedure 
Class Level Information 
Class Levels Values 
TON 3 HYE HYO ISO 
Number of observations in data set= 9 
Dependent Variable: M50 
Sum of Mean 
Source OF Squares Square FValue Pr> F 
Model 2 10.10816089 5.05408044 2.34 0.1773 
Error 6 12.95668267 2.15944711 
Corrected Total 8 23.06484356 
Source OF Anova SS Mean Square F Value Pr> F 
TON 2 10.10816089 5.05408044 2.34 0.1773 
Dependent Variable: M90 
Sum of Mean 
Source OF Squares Square F Value Pr> F 
Model 2 6821.6386727 3410.8193363 12.02 0.0080 
Error 6 1703.2526833 283.87544 72 
Corrected Total 8 .8524.8913560 
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STATISTICAL ANALYSIS OF MALVERN DA TA 
FORMULATION VARIABLE - CONCENTRATION OF ENHANCER 
Analysis of Variance Procedure 
Dependent Variable: MSO 
Source 
Model 
Error 
DF 
Sum of 
Squares 
Mean 
Square 
1 1008.8066667 1008.8066667 
4 22 .7437333 5.6859333 
Corrected Total 5 1031.5504000 
R-Square c.v. RootMSE 
0.977952 4.097113 2.3845195 
Dependent Variable: M90 
Source 
Model 
Error 
Sum of 
OF Squares 
Mean 
Square 
1 6591.5461500 6591.5461500 
4 95.5715333 23.8928833 
Corrected Total 5 6687.1176833 
R-Square C.V. Root MSE 
0.985708 4.891867 4.8880347 
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F Value Pr> F 
177.42 0.0002 
M50 Mean 
58.200000 
F Value Pr> F 
275.88 0.0001 
M90 Mean 
99.921667 
( 
STATISTICAL ANALYSIS OF MALVERN DATA 
DEVICE VARIABLE - MECHANISM OF PUMP 
Analysis of Variance Procedure 
Dependent Variable: MSO 
Sum of Mean 
Source OF Squares Square F Value Pr> F 
Model 1 13.89281667 13.89281667 5.30 0.0828 
Error 4 10.48746667 2.62186667 
Corrected Total 5 24.38028333 
R-Square c.v. Root MSE M50 Mean 
0.569838 3.527836 1.6192179 45.898333 
Dependent Variable: M90 
Sum of Mean 
Source OF Squares Square F Value Pr> F 
Model 1 1341.6130667 1341.6130667 2.16 0.2155 
Error 4 2483.1138667 620.7784667 
Corrected Total 5 3824.7269333 
R-Square c.v. Root MSE M90Mean 
0.350774 27.20223 24.915426 91.593333 
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STATISTICAL ANALYSIS OF MALVERN DATA 
DEVICE VARIABLE - SPRAY ANGLE 
Analysis of Variance Procedure 
Gass Level Information 
Gass Levels Values 
ANGLE 3 600 350 200 
Number of observations in data set= 9 
Dependent Variable: M50 
Sum of Mean 
Source OF Squares Square F Value Pr> F 
Model 2 10.13763200 5.06881600 2.45 0.1670 
Error 6 12.42667200 2.07111200 
Corrected Total 8 22.56430400 
Source OF Anova SS Mean Square F Value Pr> F 
ANGLE 2 10.13763200 5.06881600 2.45 0.1670 
Dependent Variable: M90 
Sum of Mean 
Source DF Squares Square F Value Pr> F 
Model 2 3143.8714729 1571.9357364 4.45 0.0653 
Error 6 2118.8262373 353.1377062 
Corrected Total 8 5262.6977102 
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ST A TISTICAL ANALYSIS OF MAL VERN DA TA 
DEVICE VARIABLE - ORIFICE DIAMETER 
Analysis of Variance Procedure 
Dependent Variable: MSO 
Sum of Mean 
Source OF Squares Square F Value Pr> F 
Model 2 10.19342222 5.09671111 2.36 0.1749 
Error 6 12.93220000 2.15536667 
Corrected Total 8 23.12562222 
R-Square c.v. Root MSE M50 Mean 
0.440785 3.198202 1.4681167 45.904444 
Dependent Variable: M90 
Sum of Mean 
Source OF Squares Square F Value Pr> F 
.Model 2 5899.8090667 2949. 9045333 10.03 0.0122 
Error 6 1764.5765333 294.0960889 
Corrected Total 8 7664.3856000 
R-Square C.V. Root MSE M90 Mean 
0.769769 19.42742 17.149230 88.273333 
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General Linear Models Procedure 
Scheffe's test for variable: Y 
NOTE: This test controls the type I experimentwise error rate 
but generally has a higher type II error rate than REGWF 
for all pairwise comparisons 
Alpha= 0.05 df= 26 MSE= 8012872 
Critical Value of F= 4.22520 
Minimum Significant Difference= 1939.5 
Means with the same letter are not significantly different. 
Scheffe Grouping Mean N VIS 
A 4775.8 18 1 
A 2957.8 18 76 
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Scheffe's test for variable: Y 
NOTE: This test controls the type I experimentwise error rate 
but generally has a higher type II error rate than REGWF 
for all pairwise comparisons 
Alpha= 0.05 df= 26 MSE= 8012872 
Critical Value of F= 3.36902 
Minimum Significant Difference= 2999.7 
Means with the same letter are not significantly different. 
Scheffe Grouping Mean N TON 
A 
A B 
B 
6319 12 
3612 12 
1760 12 
100 
600 
300 
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Gener;il Lineu Models Procedure 
Scheffe's test for vari;ible: 
NOTE: Thi s test controls the type I experimentwise error rate 
but ge ner;ill y h;is <1 higher type II error rnte than REGWF 
for all pairwise comparisons 
Alph;i= 0.05 df= 26 MSE= 801287 
Critical Value of F= 4.22520 
Minimum Significant Difference= 1939.5 
Means with the s;ime letter are not signific;intly different. 
Scheffe Grouping Mean N DMPG 
A 5331.1 18 1.0 
B 2402.6 18 0 
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General Linear Models Procedure 
T tests (LSD) for variable: Y 
NOTE: This test controls the type I comparisonwise error rate 
not the experimentwise error rate. 
Alpha= 0.05 df= 26 MSE= 8012872 
Critical Value of T= 2.06 
Least Significant Difference= 1939.5 
Means with the same letter are not significantly different. 
T Grouping Mean N VIS 
A 4775.8 18 1 
A 2957.8 18 76 
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General Linear Models Procedure 
T tests (LSD) for variable: Y 
NOTE: This test controls the type I comparison wise error rate 
not the experirnentwise error rate . 
Alpha= 0.05 df= 26 MSE= 8012872 
Critical Value of T= 2.06 
Least Significant Difference= 2375.4 
Means with the same letter are not significantly different. 
T Grouping Mean N TON 
A 6319 12 100 
B 3612 12 600 
B 1670 12 300 
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General Linear Models Procedure 
T tests (LSD) for variable: Y 
NOTE: This test controls the type I comparison wise error rate 
not the experimentwise error rate. 
Alpha= 0.05 df= 26 MSE= 8012872 
Critical Value of T= 2.06 
Least Significant Difference= 1939.5 
Means with the same letter are not significantly different. 
TGrouping Mean N DMPG 
A 5331.1 18 1.0 
B 2402.6 18 0 
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Source OF Type I SS F Value Pr> F 
VIS 1 29745956.016 3.71 0.0650 
DMPG 1 77188149.634 9.63 0.0046 
TON 2 130842909.196 8.16 0.0018 
DMPG*TON 2 59202705.613 3.69 0.0387 
VIS*TON 2 62767100.747 3.92 0.0326 
VIS*DMPG 1 888473.395 0.11 0.7418 
Dependent Variable: Y 
Source OF Type II SS F Value Pr> F 
VIS 1 29745956.016 3.71 0.0650 
DMPG 1 77188149.634 9.63 0.0046 
TON 2 130842909.196 8.16 0.0018 
DMPG*TON 2 59202705.613 3.69 0.0387 
VIS*TON 2 62767100.747 3.92 0.0326 
VIS*DMPG 1 888473.395 0.11 0.7418 
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Dependent Variable: Y 
Source OF Type III SS F Value Pr> F 
VIS 1 29745956.016 3.71 0.0650 
DMPG 1 77188149.634 9.63 0.0046 
TON 2 130842909.196 8.16 0.0018 
DMPG .. TON 2 59202705.613 3.69 0.0387 
VIS .. TON 2 62767100.747 3.92 0.0326 
VIS .. DMPG 1 888473.395 0.11 0.7418 
Dependent Variable: Y 
Source OF Type IV SS F Value Pr> F 
VIS 1 29745956.016 3.71 0.0650 
DMPG 1 77188149.634 9.63 0.0046 
TON 2 130842909.196 8.16 0.0018 
DMPG,.TON 2 59202705.613 3.69 0.0387 
VIS,.TON 2 62767100.747 3.92 0.0326 
VIS,.DMPG 1 888473.395 0.11 0.7418 
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PROCGLM; 
CLASS VIS DMPG TON; 
MODEL Y = VIS DMPG TON DMPG*TON TON*VIS VIS*DMPG/SSI SS2 SS3 
SS4; 
MEANS VIS DMPG TON/SCHEFFE; 
MEANS VIS DMPG TON/LSD; 
RUN; 
PROCRSREG; 
MODEL Y = VIS DMPG TON I PREDICT; 
RIDGE MAX; 
RUN; 
DATA A; DMPG = l; 
VIS= -20; 
DO I= 1TO5; 
TON= O; 
VIS = VIS+20; 
DOJ= 1 T06; 
TON = TON + 100; 
Y = 7610.88 -17.01*VIS+13237*DMPG - 39.68 .. TON + 16.76*DMPG*VIS 
- 0.034*TON*VIS - 24.07*TON*DMPG + 0.058*TON*TON; 
OUTPUT; 
END; 
END; 
PROCPRINT; 
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Coding Coefficients for the Independent Variables 
Factor Subtracted off Divided by 
VIS 
DMPG 
TON 
38.500000 37.500000 
0.250000 0.250000 
350.000000 250.000000 
Response Surface for Variable Y 
Response Mean 
Root MSE 
R-Square 
3866.841889 
3120.984519 
0.5207 
Coef. of Variation 80.7115 
Degrees of Type I Sum 
Regression Freedom of Squares R-Square 
Linear 3 137385648 0:2415 
Quadratic 1 100391366 0.1764 
Crossproduct 3 58457705 0.1027 
Total Regress 7 296234720 0.5207 
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F-Ratio 
4.702 
10.307 
2.000 
4.345 
Prob> F 
0.0088 
0.0033 
0.1368 
0.0023 
( 
Degrees 
of Parameter Standard T for HO: 
Parameter Freedom Estimate Error Parameter=O 
INTERCEPT 1 7610.872353 2403.668564 3.166 
VIS 1 -17.017080 29.852014 -0.570 
DMPG 1 13237 4503.851317 2.939 
TON 1 -39.680564 13.970208 -2.840 
VIS*VIS 0 0 
DMPG*VIS 1 16.757132 55.484169 0.302 
DMPG*DMPG 0 0 
( TON*VIS 1 -0.034236 0.067505 -0.507 
TON*DMPG 1 -24.075277 10.125811 -2.378 
TON*TON 1 0.059433 0.018513 3.210 
Parameter Estimate from Coded 
Parameter Prob> ITI Data 
INTERCEPT 0.0037 1250.697729 
VIS 0.5732 -930.395314 
DMPG 0.0065 1363.966125 
TON 0.0083 -1353.585583 
VIS*VIS 0 
DMPG*VIS 0.7649 157.098111 
DMPG*DMPG 0 
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Parameter 
TON*VIS 
TON*DMPG 
TON*TON 
Degrees 
of 
Factor Freedom 
VIS 3 
DMPG 3 
TON 4 
Parameter Estimate from Coded 
Prob> ITI Data 
0.6160 -320.966371 
0.0245 -1504.704792 
0.0033 3714.566354 
Sum of 
Squares Mean Square 
33139861 11046620 
133140423 44380141 
188412141 47103035 
Canonical Analysis of Response Surface 
(based on coded data) 
Factor 
VIS 
DMPG 
TON 
Critical Value 
Coded 
47.250043 
17.853221 
5.839590 
Uncoded 
1810.376607 
4.713305 
1809.897426 
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F-Ratio Prob> F 
1.134 0.3523 
4.556 0.0101 
4.836 0.0043 
Coded Uncoded Factor Values 
Radius VIS 
0.0 38.500000 
0.1 37.221271 
0.2 36.525396 
0.3 36.167287 
0.4 35. 990575 
0.5 35. 917028 
DMPG 
0.250000 
0.263987 
0.274531 
0.282944 
0.290160 
0.296676 
TON 
350.000000 
331.113469 
308.467457 
284.441931 
259.959596 
235.327136 
Coded Uncoded Factor Values 
Radius VIS 
0.6 35.906673 
0.7 35.937585 
0.8 35.996872 
0.9 36.076490 . 
1.0 36.171171 
DMPG 
0.302752 
0.308538 
0.314121 
0.319558 
0.324886 
TON 
210.650463 
185.968059 
161.293960 
136.632759 
111.985288 
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SIMULATED DATA FOR RESPONSE SURFACE ANALYSIS 
OBS DMPG VIS TON J y 
1 0.5 0 1 100 1 9637.88 
2 0.5 0 1 200 2 6206.38 
3 0.5 0 1 300 3 3934.88 
4 0.5 0 1 400 4 2823.38 
5 0.5 0 1 500 5 2871.88 
6 0.5 0 1 600 6 4080.38 
7 0.5 20 2 100 1 9397.28 
8 0.5 20 2 200 2 5897.78 
9 0.5 20 2 300 3 3558.28 
10 0.5 20 2 400 4 2378.78 
11 0.5 20 2 500 5 2359.28 
12 0.5 20 2 600 6 3499.78 
13 0.5 40 3 100 1 9156.68 
14 0.5 40 3 200 2 5589.18 
15 0.5 40 3 300 3 3181.68 
16 0.5 40 3 400 4 1934.18 
17 0.5 40 3 500 5 1846.68 
18 0.5 40 3 600 6 2919.18 
19 0.5 60 4 100 1 8916.08 
20 0.5 60 4 200 2 5280.58 
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SIMULATED DATA FOR RESPONSE SURFACE ANALYSIS 
OBS DMPG VIS TON J y 
21 0.5 60 4 300 3 2805.08 
22 0.5 60 4 400 4 1489.58 
23 0.5 60 4 500 5 1334.08 
24 0.5 60 4 600 6 2338.58 
25 0.5 80 5 100 1 8675.48 
f 
26 0.5 80 5 200 2 4971.98 
27 0.5 80 5 300 3 2428.48 
28 0.5 80 5 400 4 1044.98 
29 0.5 80 5 500 5 821.48 
30 0.5 80 5 600 6 1757.98 
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